Kaiser Family Foundation/LA Times Survey Of Adults With Employer-Sponsored Insurance

Authors: Liz Hamel, Cailey Muñana, and Mollyann Brodie
Published: May 2, 2019

Overview

The Survey Of Adults With Employer-Sponsored Health Insurance – the first partnership project conducted jointly by the Kaiser Family Foundation and the Los Angeles Times – explores the attitudes and experiences of adults with employer-sponsored health insurance (ESI), including views of their health plans and affordability challenges related to premiums, deductibles, and unexpected medical bills.

The survey takes a special look at those in high deductible plans (including those paired with a health savings account or HSA), those with chronic health conditions, and those with lower incomes. It also examines factors related to health plan decision-making and cost-conscious health care shopping behaviors, as well as overall views of the U.S. health care system.

Read The Los Angeles Times’ coverage:

Health insurance deductibles soar, leaving Americans with unaffordable bills

Three kids, a health plan and $15,000 in medical debt: A working family tries to make ends meet

Soaring insurance deductibles and high drug prices hit sick Americans with a ‘double whammy’

Rising health insurance deductibles fuel middle-class anger and resentment

Americans’ struggles with medical bills are a foreign concept in other countries

Trying to shop for medical care? Lots of luck with that

Not everyone has eye-popping deductibles: How one union kept medical bills in check

Executive Summary

Since the passage of the Affordable Care Act (ACA) in 2010, much attention has been paid to the parts of the U.S. health insurance landscape that were most directly impacted by the law, including the individual insurance market and expanded Medicaid programs in some states. Yet, the number of people covered by employer-sponsored health insurance in the U.S. far exceeds the number covered in the individual market or by any government program. In 2017, about 156 million people had employer-based coverage, representing almost half the total U.S. population and 60 percent of non-elderly adults.1  Surveys of employers point to the growing cost burden of health insurance for this population. Between 2008 and 2018, premiums for employer-sponsored insurance plans increased 55 percent, twice as fast as workers’ earnings (26 percent). In addition, workers are finding themselves on the hook for bigger deductibles before their insurance will kick in. Over the same time period (2008-2018), the average health insurance deductible for covered workers increased by 212 percent.2 

Against this backdrop, the Kaiser Family Foundation partnered with the Los Angeles Times to conduct a representative survey of adults with employer-sponsored health insurance.3  Some key themes from the survey are summarized here, and a full report of the findings follows.

Overall, the survey finds that most people with employer-sponsored insurance (ESI) are generally satisfied with their health plans, and large shares say they feel “grateful” and “content” about their insurance while fewer say they are “angry” or “frustrated.” However, insurance does not offer iron-clad protection against health care affordability challenges. Four in ten report that their family has had either problems paying medical bills or difficulty affording premiums or out-of-pocket medical costs, and about half say someone in their household skipped or postponed some type of medical care or prescription drugs in the past year because of the cost. Seventeen percent say they’ve had to make what they feel are difficult sacrifices in order to pay health care or insurance costs; for some, the sacrifices they report making are extreme.

The experiences and attitudes of people with employer coverage differ vastly depending on whether they are in a higher or lower deductible plan. The higher the deductible, the more likely an individual is to have negative views of their health plan, and the more likely they are to experience problems affording care or to put off care due to cost. One reason people with higher deductibles are having trouble affording care is that many of them do not have enough savings to cover the full amount of their deductible. Among those in the plans with the highest deductibles (at least $3,000 for an individual or $5,000 for a family), over half say the amount of savings they could easily access in the short term is less than the amount of their deductible.

Another group that is particularly vulnerable to health care affordability issues are those with chronic conditions. Just over half (54 percent) of those with employer-sponsored coverage say that someone covered by their plan has a chronic condition such as hypertension, asthma, a serious mental health condition, or diabetes. About half of this group reports that their family has had problems paying medical bills or difficulty affording premiums or out-of-pocket costs, compared to about three in ten of those in families without a chronic condition. The combination of a chronic condition and a high deductible leads to even higher rates of problems and worries. For example, three-quarters of those in the highest deductible plans who say someone on in their family has a chronic condition say that a family member in their household has skipped or delayed some type of medical care or prescription drugs for cost reasons in the past year.

The survey also finds that cost has taken on greater importance in health insurance decision-making over the last decade and a half. When asked to choose the most important feature in a health plan, about six in ten people with employer coverage choose cost-related factors (low premiums, deductibles, or co-pays), while about a quarter choose coverage-related factors (choice of providers or range of covered benefits). These shares are essentially the opposite of what they were in 2003, when one-third chose cost-related factors and six in ten chose range of benefits or choice of providers. Similarly, among those whose employer offered a choice of plans, the share who say they picked their plan based on the cost increased from 21 percent in 2003 to 36 percent in the current survey.

Seven in ten people with employer coverage report engaging in some type of cost-conscious health care shopping behavior in the past 12 months, the most common of which is asking for a generic instead of a brand-name drug (47 percent). Less common behaviors are those that might actually lead to lower prices on services, including shopping around at different providers to find the best price for a medical service (17 percent) and trying to negotiate with a provider for a lower price (9 percent). One selling point of high deductible health plans is that they may incentivize enrollees to engage in more cost-conscious behaviors, including price-based shopping. The survey finds mixed evidence that this is the case; while the lowest rate of reporting these behaviors occurs among those in plans with no deductible, with a few exceptions, those in high deductible plans are not significantly more likely than those in lower deductible plans to report engaging in price-based shopping. In addition, those in high deductible plans paired with a health savings account (HSA plans) are not significantly more likely than those in plans with similar deductible levels to report shopping for lower-priced health care services. Overall, those enrolled in HSA plans – who make up 18 percent of adults with employer coverage – are more likely to view them as a way to pay for current medical bills than as a way to save money for the future.

Confusion and lack of access to cost information can also be a barrier for individuals to engaging in cost-conscious health care behaviors. Two-thirds say it is difficult to find out how much medical treatments and procedures provided by different doctors and hospitals would cost them, and over four in ten say they have had difficulty understanding how much they will have to pay out of their own pocket when they use care.

Finally, while most people with employer insurance feel that the cost of health care for people like them is too high, more say the current U.S. health insurance system works well for people with employer coverage than say it works well for people on Medicare or Medicaid or those who purchase their own insurance. Asked who is to blame for high costs, majorities point the finger at pharmaceutical and insurance companies, while fewer see hospitals, doctors, or employers as deserving of blame.

Key Findings: Section 1: Profile Of Adults With Employer-sponsored Health Insurance And Overall Views Of Coverage

Sixty percent of adults ages 18-64 in the United States have health insurance coverage through an employer or union. Census data show that, compared to the general population, these adults have higher incomes and education levels and are more likely to be White or Asian and less likely to be Black or Hispanic.4 

The survey finds that most people with employer-sponsored health coverage (73 percent) say they pay at least part of their premium for their insurance, while 16 percent say their employer pays the whole thing. When asked about their annual deductible for medical care, 15 percent say they have no deductible and 44 percent report a deductible of less than $1,500 for an individual or less than $3,000 for a family (defined for the purposes of this report as “lower deductible”). Four in ten (41 percent) report having plans with higher deductible amounts, including 20 percent with deductibles between $1,500 and $2,999 for an individual or between $3,000 and $4,999 for a family (“higher deductible”) and 21 percent with deductibles of at least $3,000 for an individual or $5,000 for a family (“highest deductible”). About one in six (18 percent) report having a higher or highest deductible plan paired with a health savings account (HSA).

Figure 1: Four In Ten Adults With Employer-Sponsored Insurance Report Having High Deductible Plans

Nearly two-thirds (64 percent) of people with employer coverage say their insurance covers other family members in addition to themselves, while 36 percent report having single coverage. While nearly nine in ten (88 percent) describe their own health status as “excellent,” “very good,” or “good,” just over half (54 percent) say that they or another family member covered by their plan has a chronic condition, the most common being hypertension or high blood pressure (30 percent), a serious mental health condition (15 percent), asthma or other breathing problems (14 percent), and diabetes (11 percent).

Figure 2: Half of Those With Employer-Sponsored Insurance Say They Or A Family Member Has At Least One Chronic Condition

Overall, most people with employer coverage report being happy with their insurance. Nearly seven in ten (68 percent) give their health plan a grade of “A” or “B,” and large shares say the words “grateful” (72 percent) and “content” (69 percent) describe the way they feel about their insurance, while far fewer identify with words like “frustrated” (26 percent), “confused” (23 percent), or “angry” (14 percent). More than half (58 percent) say they think their employer is offering them the best health insurance they can afford. However, a substantial share – 42 percent – believe their employer could be providing something better.

It’s notable that these views differ greatly depending on the deductible level of an individual’s plan. For example, among those in the highest deductible plans, over half (55 percent) give their plan a grade of “C” or below, and half (51 percent) say their employer could be providing something better. While positive emotions still outweigh negative emotions for this group, the gap is much narrower, with 58 percent saying they feel “grateful,” and 50 percent “content,” while four in ten say they feel “frustrated,” 34 percent “confused,” and 23 percent “angry.”

Figure 3: Most Give Plans Passing Grades, But Less So For Those With High Deductibles
Figure 4: Most Say Employer Is Offering Best Insurance They Can, But Those With Highest Deductibles More Split
Figure 5: Positive Emotions Towards Health Plans Outweigh Negatives, But Less So For Those With High Deductibles

In addition, while most people in plans with no or lower deductibles say their health insurance has “stayed about the same” in the past 5 years, four in ten (39 percent) of those in higher deductible plans and half of those in the highest deductible plans say their insurance has “gotten worse.”

Figure 6: Those In High Deductible Plans More Likely To Say Insurance Has Gotten Worse In Past 5 Years

Key Findings: Section 2: Affordability Of Health Care And Insurance

While many employers pay for a large share of covered workers’ health insurance premiums, the survey finds that employer-sponsored health insurance does not offer iron-clad protection against health care affordability challenges. Four in ten adults with employer coverage say that in the past year they had problems paying medical bills or difficulty affording their premium, deductible, co-pays, or an unexpected medical bill for themselves or a family member. When this group is asked to say which has been the biggest problem for their family, medical bills they had to pay before meeting their deductible (31 percent) and unexpected medical bills (23 percent) top the list, while fewer say the biggest burden is their prescription drug costs (11 percent), medical visit co-pays (10 percent), or health insurance premiums (8 percent).

Figure 7: Four In Ten People With Employer Coverage Report Difficulty Affording Some Type Of Health Care Or Insurance Cost
Figure 8: Deductibles And Surprise Medical Bills Top List Of Most Difficult Affordability Problems

Among the 40 percent who report problems affording some type of health care cost in the past year, many report making various sacrifices in order to pay these costs. Two-thirds of this group (representing about a quarter of all adults with ESI) say they put off vacations or major household purchases or cut back spending on food, clothing, or basic household items. About half (one in five among the total) say they increased their credit card debt or used up all or most of their savings to pay for health care. One-third (14 percent of total) say they took on an extra job or worked more hours and a quarter (10 percent of total) reporting borrowing money from friends or family or taking money out of a long-term savings account. Smaller shares say they took out a loan, sought the aid of a charity or non-profit, changed their living situation, or used the internet to raise funds to pay for medical care.

Figure 9: Those With Employer Coverage Who Have Problems Affording Health Care Report Many Sacrifices To Pay Bills

In addition, 41 percent of those who had difficulty affording health care costs (17 percent of all adults with employer-sponsored insurance) say they feel they have had to make a difficult sacrifice in order to pay health care or insurance costs in the past 12 months. When asked to describe in their own words the most difficult sacrifice they have made, responses ranged from cancelled vacations, to skipped meals, to increased debt, to forgoing needed medical care.

Table 1: In Their Own Words: Difficult Sacrifices To Afford Health Care
Question: What is the most difficult sacrifice you’ve made in order to pay health care or health insurance costs in the past 12 months?
CategoryPercentage among those who made a difficult sacrificePercentage among all adults with ESIOpen-ended responses
Cut back on extras (vacation, eating out, entertainment)17%3%“Not being able to have extra money to do leisure/recreational things I would like. Have to focus money on ‘needs’ not ‘wants.’”

“Cancelled 25th wedding anniversary plans/vacation”

Cut back on food/eat less122“Having trouble affording food for my kid and myself”

“Me not eating so my kids can”

“Ate like a bird sometimes”

Skipping/being late on other bills102“I missed several car payments”

“Picking which bill to pay and not to pay”

Taking money out of savings/not able to save102“Take money out of my 401k and personal savings account”

“Not being able to save/put away money”

Cut back in general71“Cutting our budget everywhere”

“Cut back on everything”

Increasing credit card/other debt71“Raising my credit card debt so much. Now with interest I only have to pay more.”

“Taking out more debt to pay down a medical bill”

Increasing work hours/going back to work71“I had to work 3 jobs at once. 1 full time and 2 part time jobs. Working from 4:30AM until 11pm”
Skipping care/medication71“Allowing my health to deteriorate because it’s too expensive to keep up with the cost of care”

“Not getting the medical treatment I need. I need two surgeries and cannot afford them at this time.”

Cut back on clothing, children’s items61“Not getting gifts for my grandchildren, birthdays and holidays”

“Cut back on purchases for our children, such as clothes”

Unpaid medical bills can also lead to longer-term financial effects for some people. About one in five (19 percent) say that someone in their household has been contacted by a collection agency in the past 12 months because of medical bills, and 9 percent say they have at some point declared personal bankruptcy because of medical bills (including 2 percent who say they did so in the past 12 months).

In addition to making sacrifices to afford care, about half (51 percent) of adults with employer health coverage report that they or someone in their household has skipped or delayed some type of medical care or prescription drugs in the past 12 months because of the cost. This includes about a third each who report relying on home remedies or over-the-counter drugs instead of going to see a doctor (35 percent) or putting off or postponing needed care (33 percent), about a quarter (24 percent) who report not getting a recommended medical test or treatment, and about one in five (18 percent) who report not filling a prescription, cutting pills in half, or skipping doses of medicine because of the cost.

Figure 10: Half Of Those With ESI Say Someone In Family Skipped Or Postponed Needed Care Or Rx Because Of The Cost

Both difficulty affording health care expenses and forgoing or delaying care due to cost are more commonly reported among certain groups, including those with lower incomes, those in higher deductible plans, and those who say someone covered by their plan has a chronic health condition. For example, while 40 percent of all adults with employer coverage say they’ve had problems paying medical bills or difficulty affording health care or insurance costs for themselves or their family in the past year, the shares are higher among those with annual household incomes below $40,000 (65 percent), those who say someone covered by their plan has a chronic condition (49 percent), and those in the highest deductible plans (49 percent). Similarly, while about half overall report that someone in their household skipped or postponed some type of health care in the past year because of the cost, the share rises to around six in ten among those with the lowest incomes, the highest deductibles, or a chronic condition.

Figure 11: Lower Incomes, Higher Deductibles, And Chronic Conditions Associated With Health Care Affordability Challenges
Figure 12: Lower Incomes, High Deductibles, And Chronic Conditions Associated With Skipping Or Postponing Care Due To Cost

Key Findings: Section 3: The Experiences Of Those With High Deductibles And Those With Chronic Conditions

As noted above, people with employer sponsored health plans that have high deductibles are more likely to report problems affording health care, and more likely to postpone or forgo health care services for cost reasons. One contributing factor may be the fact that many people in higher deductible plans do not have enough savings to cover the full amount of their deductible. When asked how much they have in savings that could easily be accessed in the short term, three in ten (31 percent) of those in higher deductible plans and more than half (56 percent) of those in the highest deductible plans name an amount that is less than the amount of their deductible.

Figure 13: Over Half Of Those In Highest Deductible Plans Report Personal Savings Less Than Amount Of Their Deductible

In addition, most people enrolled in plans with high deductibles say they would not be able to pay a bill equal to the full amount of their deductible without going into debt. When asked how they would pay an unexpected medical bill equal to the amount of their deductible, one-third of those in plans with high deductibles say they would either pay the bill at the time of service or put it on a credit card and pay it off at their next statement. About half say they would go into some type of debt to pay the bill, either by putting it on a credit card and paying it off over time (27 percent), setting up a payment plan with the provider (17 percent), or borrowing money from a bank, payday lender, or friends and family (5 percent). One in six (16 percent) say they would not be able to pay such a bill at all.

Those in high deductible plans who have lower incomes are even less likely to say they could afford such a bill. Among those in high deductible plans who have annual household incomes of $40,000 or less, one-third (32 percent) say they would not be able to pay a bill in the full amount of their deductible at all, while just 14 percent say they would pay it off right away or at the next credit card statement.

Figure 14: Two-Thirds In Higher Or Highest Deductible Plans Could Not Pay A Bill Equal To Deductible Without Going Into Debt
Figure 15: One-Third Of Those With Low Incomes And High Deductibles Would Not Be Able To Pay Bill Equal To Deductible

Another group that is particularly vulnerable to health care affordability issues are people with chronic conditions. Those who say someone covered by their plan has a chronic health condition (a group that makes up 54 percent of people with employer plans) are about twice as likely as others to report problems paying medical bills (36 percent versus 16 percent). They are also much more likely to say they’ve had difficulty affording medical bills before meeting their deductible, unexpected medical bills, co-pays, and monthly health insurance premiums.

Figure 16: Those In Families With A Chronic Health Condition More Likely To Experience Problems Affording Health Care

Drilling down into the consequences of these affordability problems reveals more about the financial burden of health care on families with chronic conditions. Overall, more than one-third of those with a chronic condition in the family say they put off vacations or major household purchases (36 percent) or cut back spending on food, clothing, or basic household items (35 percent) in order to pay for health care and insurance costs. Nearly three in ten (28 percent) say they increased their credit card debt, about a quarter (26 percent) say they used up all or most of their savings, and one in five (19 percent) say they took on an extra job or worked more hours in order to pay for health care. Other consequences, such as borrowing money, seeking charity aid, or changing living situation were less common, but still occurred at about twice the rate among people in families with a chronic condition compared to those without such a condition.

Figure 17: Those In Families With Chronic Health Conditions More Likely To Report Financial Impacts Of Health Care Affordability Problems

Those with chronic conditions are also more likely to report forgoing or delaying health care because of the cost, and this is particularly true for those in plans with high deductibles. For example, 42 percent of those who say someone covered by their plan has a chronic condition say there was a time in the past year when they or another family member put off or postponed getting health care they needed, compared with 23 percent of those without a chronic condition. Among those with chronic conditions who are in the highest deductible plans, the share rises to 60 percent. Similarly, three in ten (31 percent) of those in families with a chronic condition say they skipped a doctor-recommended test or medical treatment in the past year for cost reasons, twice the share as among those with no chronic condition, and rising to 44 percent among those with chronic conditions in the highest deductible plans. Overall, 60 percent of all those with a family chronic condition say someone in their household skipped or postponed some type of care or medicine for cost reasons, rising to 75 percent among those in the highest deductible plans.

Table 2: Skipping And Postponing Needed Care Because Of Cost, By Family Chronic Condition And Health Plan Deductible Level
Percent who say they or a family member did the following in the past 12 months…No chronic condition in familyAny family member covered by plan has chronic condition
TotalNo/Lower DeductibleHigher DeductibleHighest Deductible
Put off or postponed getting health care they needed23%42%34%49%60%
Relied on home remedies or OTC drugs instead of going to see a doctor2841334658
Have not gotten a medical test or treatment recommended by a doctor1531243544
Not filled a prescription, cut pills in half, or skipped doses of a medicine1223192335
Yes to any4060526975

The combination of a chronic condition and a high deductible can also lead families to worry about affording health care in the future. For example, among those with a chronic condition in the family, about half of those in the highest deductible plans say they are not confident in their ability to pay for the usual medical costs they and their family require, and almost two-thirds are not confident they could pay for a major illness.

Figure 18: Among Those With High Deductibles And Chronic Conditions, Large Shares Are Not Confident About Affording Major Illness

Key Findings: Section 4: Health Insurance Decision-making And Trade-offs

The survey finds that at the same time premiums and deductibles have been rising for people with employer-sponsored coverage, cost has taken on greater importance in health insurance decision-making compared to previous years. For example, when asked to choose the most important feature in a health plan, one quarter cite a low monthly premium, 18 percent choose a low deductible, and 16 percent cite low co-pays, amounting to six in ten (59 percent) choosing a cost-related factor. About a quarter (26 percent) choose coverage-related factors including having a wide range of benefits (17 percent) or a wide choice of doctors and hospitals (10 percent). These shares are essentially reversed from a KFF survey conducted in 2003, when one-third of people with employer coverage chose cost-related factors as the most important feature in a health plan and six in ten chose a wide range of benefits or choice of providers.

Figure 19: Cost Factors Rated More Important Now Than In 2003, Benefits And Provider Choice Less Important

Another trend point shows a similar pattern. Among those whose employer offered a choice of plans, the share who say they picked their plan based on the cost increased 15 percentage points, from 21 percent in 2003 to 36 percent in the current survey.

Figure 20: Compared To 2003, Cost Now Rated More Important, Choice Of Providers Less Important In Plan Choice

When asked about trade-offs between premiums and out-of-pocket costs, people with ESI are pretty evenly divided between saying they would prefer a plan with a relatively low monthly premium and higher out-of-pocket costs (52 percent) or one with a relatively high monthly premium and lower out-of-pocket costs (47 percent). However, those with higher household incomes lean towards lower premiums and higher out-of-pocket costs, while those with lower incomes lean in the opposite direction.

Figure 21: Preference Split Between Plans With Higher Or Lower Premium, Out-Of-Pocket Costs

Despite this increased emphasis on cost, there is no great enthusiasm among people with employer plans for several trade-offs that might lower insurance premiums. About three-quarters say they would not be willing to pay a significantly higher deductible in exchange for a lower premium (perhaps because deductibles have risen so much already), and six in ten say they would not be willing to pay more for brand name prescription drugs. However, about half say they would be willing to accept a more restricted list of providers in exchange for lower premiums, and a large majority (85 percent) say they’d be willing to participate in a wellness program.

Figure 22: Most Willing To Participate In Wellness Program To Lower Premium, One In Four Willing To Pay Higher Deductible

Key Findings: Section 5: Views And Experiences Related To Health Savings Accounts

Just under one in five (18 percent) of all adults with employer coverage report being in a high deductible health plan paired with a Health Savings Account (HSA). Most of these people report making relatively modest contributions and having relatively modest savings in their HSA, particularly if they have lower incomes. For example, about half (47 percent) of people with an HSA plan say they have contributed less than $1,000 to their account in the past 12 months, and just 11 percent say they’ve contributed $5,000 or more. Among those with household incomes under $75,000 a year, 72 percent say they contributed less than $1,000 and just 3 percent put in at least $5,000.

Figure 23: Those With Higher Incomes And Highest Deductibles Report Greater HSA Contributions

Few seem to be able to save much money in these accounts over time. Overall, about three in ten (31 percent) say they have at least $2,000 saved in their HSA account, including 17 percent who have at least $5,000. Among those with incomes under $75,000, fewer – 22 percent – report having at least $2,000 saved, including one in ten (11 percent) who have at least $5,000.

Figure 24: Few Of Those With HSA Plans Report Having At Least $5,000 Saved In HSA Account

The survey finds that individuals with HSA plans are more likely to view them as a way to pay for current medical bills (68 percent) than as a way to save money for the future (32 percent). This also bears out in their self-reported behaviors: while seven in ten (72 percent) say they have used their HSA to pay medical bills in the past 12 months, far fewer – 21 percent – say they use their HSA to invest in stocks, bonds, or mutual funds.

Figure 25: HSAs Viewed More As A Way To Pay Medical Bills Rather Than Save For The Future

Key Findings: Section 6: Cost-conscious Health Care Shopping Behaviors

The survey asked about a list of seven different cost-conscious health care shopping behaviors, and finds that seven in ten people with ESI report engaging in at least one of these behaviors in the past 12 months. The most common of these are asking for a generic instead of a name brand drug (47 percent) and checking with a provider or health plan beforehand to find out the cost of a procedure (37 percent) or office visit (36 percent). Less commonly-reported behaviors are those that might actually lead to lower prices on health care services, including using an online tool to research the cost of different providers (23 percent), shopping around at different providers to find the best price for a medical service (17 percent), and trying to negotiate with a provider for a lower price (9 percent).

When consumers do try to negotiate prices, they report being successful less than half of the time; of the 9 percent who say they tried to negotiate with a provider, 43 percent say they were able to get a lower price while 57 percent say they were not.

Figure 26: Seven In Ten Report Engaging In At Least One Health Care Shopping Or Cost-Saving Behavior

One selling point of high deductible health plans is that they may incentivize enrollees to engage in more cost-conscious behaviors, including price-based shopping. The survey finds mixed evidence about whether this is occurring among people with employer-based coverage. While the lowest rates of reporting cost-conscious behaviors occur among those in plans with no deductible, those in high deductible plans are not significantly more likely than those in lower deductible plans to report engaging in most of the behaviors asked about in the survey. There are two exceptions: those in plans with high deductibles are more likely than those with lower deductibles to say they’ve asked for a generic rather than a name brand drug (55 percent versus 43 percent) and that they’ve used an online tool to compare the cost of different providers (30 percent versus 22 percent).

Similarly, HSA plans are viewed as a way to give consumers more control over their medical care and to encourage cost-conscious behaviors. To the extent that the survey finds people in HSA plans are engaging in more cost-conscious behaviors, it seems to be due to the deductibles associated with these plans rather than the savings account element, since those in high deductible plans without an HSA are not significantly more likely than those in HSA plans to report these behaviors.

Table 3: Reports Of Cost-Conscious Health Care Shopping Behaviors, By Health Plan Deductible Level And Health Savings Account Participation
Percent who say they did each of the following in the past 12 months…No deductibleLower deductibleHigher/Highest deductible
TotalNo HSAWith HSA
Asked a doctor or pharmacist for a generic drug to save money33%43%55%58%53%
Checked with a provider or health plan before a procedure or hospital stay to find out how much they have to pay2938393644
Checked with their provider or health plan before an office visit to find out how much they have to pay2936403843
Talked to a provider or health plan about the cost of a prescription drug1830333235
Used an online tool to research the cost of different health care providers922302931
Attempted to shop around at different providers to find the best price417211925
Tried to negotiate with a doctor, hospital, or other provider to get a lower price5911815
Yes to any5268797782

Confusion and lack of access to cost information can also be a barrier for individuals to engaging in cost-conscious health care behaviors. Two-thirds of people with employer coverage say it is difficult to find out how much medical treatments and procedures provided by different doctors and hospitals would cost them. In addition, four in ten say they have had difficulty understanding what their health plan will cover (40 percent) and a similar share report difficulty understanding how much they will have to pay out of their own pocket when they use care (44 percent). 

Figure 27: Most Say Cost Information Is Hard To Find, Four In Ten Report Difficulty Understanding Cover Or What They’ll Pay

Key Findings: Section 7: Perceptions Of Health System Winners, Losers, And Who’s To Blame

When asked how well the current health insurance system in the United States works for various groups, fewer than a quarter of people with employer coverage say it works “very well” for any group, with the exception of wealthy people (70 percent). Still, a large majority believes the system works at least “somewhat well” for people with employer health coverage (79 percent), somewhat higher than the share who say the same about people covered by Medicare (65 percent) or Medicaid (63 percent), and substantially higher than the share saying the system works well for those who buy their own insurance (45 percent).

Figure 28: More Say Health Insurance System Works Well For Those With Employer Coverage Than Other Coverage Types

While almost two-thirds (65 percent) of people with employer coverage feel the current health insurance system in the U.S. works at least “somewhat well” for people like them, the percentage varies by income and deductible level. For example, 80 percent of those in a plan without a deductible say the system works well for people like them, compared to about half (48 percent) of those in the plans with the highest deductibles. Similarly, about three-quarters of those with annual household incomes of at least $100,000 feel the system works well for them, compared with half (49 percent) of those with incomes under $40,000.

Figure 29: Those With Higher Deductibles, Lower Incomes Less Likely To Feel U.S. System Works Well For People Like Them

While most feel the system is working well for them, about eight in ten (78 percent) people with employer coverage say the cost of health care for people like them is too high, with near-universal agreement across demographic groups. Asked who they blame for the high cost of health care, people mainly point to two groups that have long been named by the public as culprits of high costs: pharmaceutical and insurance companies, with about six in ten saying each deserves “a lot of blame.” About three in ten also place a lot of blame on hospitals (32 percent), the Affordable Care Act (29 percent) and the Trump Administration’s recent actions on health care (28 percent), while fewer place a lot of blame on doctors (15 percent). Echoing the finding that a large majority says they feel “grateful” for their employer-provided health insurance, just 7 percent say employers deserve a lot of blame for the high cost of health care, while two-thirds say employers deserve “just a little” or “no blame at all.”

Figure 30: Pharma And Health Insurance Companies Receive Most Blame For High Costs, Employers Less So

Not surprisingly, there are partisan differences in the share who blame the Affordable Care Act (ACA) and the Trump Administration for the high cost of health care. Among those who feel costs for people like them are too high, about half (49 percent) of Democrats and just 4 percent of Republicans say the Trump Administration’s actions on health care deserve a lot of blame, while six in ten Republicans (59 percent) and just 10 percent of Democrats place a lot of blame on the ACA. Among independents, 27 percent say the ACA deserves a lot of blame and 21 percent say the same about the Trump Administration’s recent actions.

Figure 31: Across Partisans, Large Shares Blame Pharmaceutical And Health Insurance Companies For High Health Care Costs

Methods

The Kaiser Family Foundation/Los Angeles Times Survey of Adults with Employer-Sponsored Health Insurance is based on interviews with a probability-based sample of 1,407 respondents between the ages of 18 and 64 who reported having health insurance from an employer or union (excluding those covered by a parent’s employer). Interviews were administered online and by telephone from September 25 through October 9, 2018 in English and Spanish.

Teams from the Kaiser Family Foundation and The Los Angeles Times worked together to develop the questionnaire and analyze the data, and both organizations contributed financing for the survey. Each organization is solely responsible for its content.

NORC at the University of Chicago conducted sampling, interviewing, and tabulation for the survey using the AmeriSpeak Panel, a representative panel of adults age 18 and over living in the United States. AmeriSpeak Panel members are recruited through probability sampling methods using the NORC National Sample Frame, an address-based sampling frame. Panel members who do not have internet access complete surveys via telephone, and internet users complete surveys via the web (for this survey, 60 respondents completed via phone and 1,347 via web).5  For this study, panelists with lower incomes were selected at disproportionately higher rates than those with higher incomes in order to allow for separate analysis of low-income people with employer-sponsored insurance.

The combined results have been weighted to adjust for the fact that not all survey respondents were selected with the same probability, to address the implications of sample design, and to account for systematic nonresponse along known population parameters. The first weighting stage addressed differences in probability of selection for the AmeriSpeak Panel and accounted for differential nonresponse to the AmeriSpeak screening interview. At this stage, an adjustment was also made to account for the oversampling of lower-income panelists and to account for differential nonresponse to the survey screening interview.

In the second weighting stage, the sample was adjusted to match known demographic distributions of the U.S. population ages 18-64 with employer-sponsored health insurance using the following parameters: age, age by sex, age by education, gender by education, education within non-Hispanic whites, race/ethnicity, Census Division, and household income. Demographic weighting parameters were based on the U.S. Census Bureau’s March 2018 Annual Social and Economic Supplement of the Current Population Survey.

The margin of sampling error including the design effect for the full sample is plus or minus 3 percentage points. All statistical tests of significance account for the effect of weighting. Numbers of respondents and margins of sampling error for key subgroups are shown in the table below. For results based on other subgroups, the margin of sampling error may be higher. Sample sizes and margins of sampling error for other subgroups are available by request. Note that sampling error is only one of many potential sources of error in this or any other public opinion poll.

GroupN (unweighted)M.O.S.E.
Total adults ages 18-64 with employer-sponsored insurance1,407±3 percentage points
Deductible level
Zero Deductible189±9 percentage points
Lower deductible647±5 percentage points
Higher deductible280±7 percentage points
Highest deductible284±7 percentage points

Kaiser Family Foundation public opinion and survey research and NORC at the University of Chicago are both charter members of the Transparency Initiative of the American Association for Public Opinion Research.

Endnotes

  1. State Health Facts. (n.d.). Retrieved April 2019, from https://modern.kff.org/state-category/health-coverage-uninsured/ ↩︎
  2. Claxton, G., Rae, M., Long, M., Damico, A., Whitmore, H. (2018, October 3). Kaiser Family Foundation 2018 Employer Health Benefits Survey. Retrieved from https://modern.kff.org/health-costs/report/2018-employer-health-benefits-survey/ ↩︎
  3. The survey includes adults ages 18-64 who say they get their health insurance from their own or a spouse’s employer or union. Those ages 65 and older are excluded since they are generally eligible for coverage through Medicare. ↩︎
  4. State Health Facts. (n.d.). Retrieved April 2019, from https://modern.kff.org/state-category/health-coverage-uninsured/nonelderly-with-employer-coverage/ ↩︎
  5. More details on NORC’s AmeriSpeak panel, including sample frame and recruitment methods, can be found at http://www.norc.org/Research/Capabilities/Pages/amerispeak.aspx.   ↩︎

Medicaid’s Prescription Drug Benefit: Key Facts

Published: May 1, 2019

Medicaid provides health coverage for millions of Americans, including many with substantial health needs. Prescription drug coverage is a key component of Medicaid for many beneficiaries, such as children, non-elderly adults, and people with disabilities, who rely on Medicaid drug coverage for both acute problems and for managing ongoing chronic or disabling conditions. (Medicaid beneficiaries who also have Medicare receive drug coverage through Medicare.). Though the pharmacy benefit is a state option, all states cover it, and, within federal guidelines about pricing and rebates, administer pharmacy benefits in different ways. After a sharp spike in 2014 due to specialty drugs and expansion under the Affordable Care Act (ACA), Medicaid drug spending growth has slowed, similar to the overall US pattern; however, state policymakers remain concerned about Medicaid prescription drug spending as spending is expected to grow in future years. Due to Medicaid’s role in financing coverage for high-need populations, it pays for a disproportionate share of some high cost specialty drugs, and due to the structure of pharmacy benefit, Medicaid must cover upcoming “blockbuster” drugs. Policymakers’ actions to control drug spending have implications for beneficiaries’ access to needed prescription drugs. This fact sheet provides an overview of Medicaid’s prescription drug benefit and recent trends in spending and utilization.

Though generic drugs account for the large majority of drug utilization in Medicaid – 86% of prescriptions in 2017 — brand name drugs accounted for 79% of drug spending.

How does Pricing and Payment for Prescribed Drugs Work in Medicaid?

The total amount paid by Medicaid for a given drug is a factor of several inputs: 1) the dispensing fee paid to the pharmacist; 2) the amount paid to the pharmacy for the ingredients of a drug; and 3) the rebate received from the manufacturer. States have flexibility to set professional dispensing fees, but there are federal requirements for the other inputs.

Ingredient Costs and Payment

Medicaid reimburses pharmacies for the cost of drugs dispensed to beneficiaries based on the actual acquisition cost (AAC) for a drug. In general, Medicaid does not purchase drugs directly from manufacturers or wholesalers; rather, Medicaid pays for the cost of drugs dispensed to Medicaid beneficiaries through pharmacies. The federal government requires states to use AAC to set payment to pharmacies and encourages states to use the National Average Drug Acquisition Cost (NADAC) data as the measure of AAC.1 ,2  The NADAC is intended to be a national average of the prices at which pharmacies purchase a prescription drug from manufacturers or wholesalers, including some rebates.

Pharmacies that dispense drugs to Medicaid beneficiaries purchase drugs from manufacturers or wholesalers, negotiating prices for drugs. Payment between the pharmacy and the manufacturer or wholesaler (to acquire and stock the drug) is a proprietary process, negotiated based off the manufacturer-set list prices for a drug. Manufacturers do not provide public information on how they set this list price and historically have not been required to explain changes in a product’s list price. While the list prices most directly affect the wholesaler and pharmacy, they also affect Medicaid reimbursement schedules, as they are an input into the AAC.

The Medicaid Drug Rebate Program

Federal law requires manufacturers who want their drugs covered under Medicaid to rebate a portion of drug payments to the government,3  and in return, Medicaid must cover almost all FDA-approved drugs produced by those manufacturers.4 ,5  The formula for the amount of the rebate is set in statute6  and varies by type of drug (brand or generic).7  The structure of the federal Medicaid rebate factors in the “best price” charged to any other buyers and ensures that Medicaid will always receive a higher rebate than other payers, with some exceptions.8  It also includes an inflationary component that requires additional rebates when average manufacturer prices for a drug increase faster than inflation.9  Rebates apply regardless of whether a state pays for prescription drugs on a fee-for-service basis or includes them in capitation payments to managed care plans.

In addition to federal statutory rebates, most states negotiate with manufacturers for supplemental rebates. Some states have formed multi-state purchasing pools when negotiating supplemental Medicaid rebates to increase their negotiating power. In addition, Medicaid managed care plans may negotiate their own rebate agreements with manufacturers.

Statutory and supplemental rebates account for a sizeable share of gross prescription drug spending, accounting for 55% of aggregate drug spending in 2017 (Figure 1).10  In recent years, rebates as a share of gross Medicaid drug spending have increased (Figure 1), leading to flat or declining net Medicaid spending for prescription drugs. The specific rebate on a given drug is proprietary for both statutory and supplemental rebates.

Figure 1: Medicaid Drug Spending and Rebates, FY2014-17

How do states administer the Medicaid pharmacy benefit?

States are not required to cover prescription drugs under Medicaid, but all states opt to include this service in Medicaid. Within federal rules regarding the federal rebate agreement and medical necessity requirements, states have flexibility to administer and manage the pharmacy benefit within their Medicaid programs. States generally rely on two, intersecting levers to do so: 1) use of managed care and/or pharmacy benefit managers (PBMS) and 2) utilization controls.

Managed Care and Pharmacy Benefit Managers

As more states have enrolled additional Medicaid populations into managed care arrangements over time and states have included pharmacy benefits in managed care contracts, managed care organizations (MCOs) have played an increasingly significant role in administering the Medicaid pharmacy benefit. Most states contract with MCOs to provide services to Medicaid beneficiaries. Under some of these arrangements, states pay MCOs a monthly fee (capitation rate) to cover the cost of services provided to enrollees and any administrative expenses. States may include all Medicaid services in these contracts or they may “carve-out” certain services from capitation rates. Under the ACA, states are able to collect rebates on prescriptions purchased by MCOs and as a result, many states have chosen to “carve-in” the pharmacy benefit to their managed care benefits. Of the 39 states contracting with comprehensive risk-based MCOs in 2018, 35 states reported that the pharmacy benefit was carved in, with some states reporting exceptions such as high-cost or specialty drugs.11 

Many states also use pharmacy benefit managers (PBMs) in their Medicaid prescription drug programs. PBMs perform financial and clinical services for the program, administering rebates, monitoring utilization, and overseeing preferred drug lists.12  PBMs may be used regardless of whether the state administers the benefit through managed care or on a fee-for-service basis.

Utilization Management

Most states use an array of measures to control utilization of prescription drugs in Medicaid. Because most manufacturers participate in the Medicaid Drug Rebate Program,13  Medicaid essentially maintains an open formulary in which, states are required to provide nearly all prescribed drugs made by manufacturers.14 ,15  However, state Medicaid programs have used drug utilization management techniques to contain pharmacy costs for many years. Most commonly, state Medicaid programs maintain a preferred drug list (PDL) of outpatient prescription drugs,16  which is a list of drugs states encourage providers to prescribe over other drugs. A state may require a prior authorization for a drug not on a preferred drug list. Often, drugs on PDLs are cheaper or include drugs for which a manufacturer has provided supplemental rebates. Other strategies include implementing prescription limits or using state Maximum Allowable Cost (MAC)17  programs.

Following an uptick in 2014 and 2015 that reflected both the introduction of high-cost specialty drugs and increased utilization due to the ACA expansion, Medicaid prescription drug utilization and spending growth slowed in 2016 and 2017. From 2014 to 2017, Medicaid prescription drug utilization and spending largely tracked each other in the aggregate: Medicaid outpatient drug utilization increased from 621.7 million prescriptions in 2014 to 752.9 million in 2017 while spending before rebates also increased from $45.9 billion to $63.6 billion over the same period. Growth in both utilization and spending was higher from 2014-2015 than from 2015-2017. However, these aggregate amounts belie underlying changes in utilization patterns and spending for Medicaid prescription drugs. Most notably, recent years have seen changes in the mix of generic versus brand drugs and the rise of specialty drugs and biologics.

Though generic drugs account for the large majority of drug utilization in Medicaid, brand name drugs account for most drug spending. Because generic drugs are lower cost but still therapeutically equivalent to brand name drugs, most state Medicaid programs require generic substitution unless the prescriber specifies that the brand is medically necessary.18 ,19  Generic drugs accounted for the vast majority of prescription drug volume in Medicaid from 2014 through 2017. In addition, the average annual increase in number generic prescription drugs covered through Medicaid outpaced brand name drugs, leading to a small increase in their share of total prescription volume (from 84% to 86%) (Figure 2). However, generic drugs accounted for a relatively small share of Medicaid spending on drugs before rebates from 2014 through 2017, and this share declined slightly over time (from 25% to 21%) (Figure 2). This growth in brand spending reflects national trends caused by the launch of expensive new drugs during the period and price increases for some brand name drugs, such as insulin, for which there are no generic versions.20 

Figure 2: Number and Spending for Medicaid Outpatient Prescriptions, by Brand/Generic Status, 2014-2017

While generics are less expensive than brand name drugs, the cost of generics has also been rising in recent years.21  These price increases reflect a combination of factors including decreasing competition within the generic market and drop in the number of generic manufacturers, as well as delays in FDA generic approvals, supply or manufacturing challenges for come drugs, among others.22  Despite the inflationary component in the rebate calculation, the complex, interrelated nature of pricing and reimbursement means that cost increases are not necessarily limited for generic drugs in Medicaid. Additionally, some believe that even limiting Medicaid spending for generics to inflation is problematic, as the expectation is that the price of generic drugs will decline over time due to competition.

In recent years, much attention in Medicaid pharmacy issues has been focused on high-cost blockbuster or “specialty” drugs, which are generally drugs that are expensive and/or require special administration. The most notable example of this attention is direct acting antivirals (DAAs), such as Sovaldi and Harvoni, used to treat hepatitis C (HCV). These drugs were a major advance in the treatment of HCV but carried a list price (initially $84,000 for a course of treatment with Sovaldi) that posed a challenge to state Medicaid program financing, even with the required rebate. Because a disproportionate number of people with HCV are enrolled in public programs, Medicaid financed a large share of DAA treatment.23  Increased competition within the class has led to some decline in list prices,24  but DAAs remain expensive, and antivirals account for a substantial share of Medicaid drug spending.25  Some states, such as Louisiana and Washington, are pursuing new approaches to further manage DAA costs while extending or maintaining access for people with HCV (see Box 1).

A related area of focus in recent years is biologics, which are products, such as drugs or vaccines, derived from living organisms with chemical structures more complicated than traditional small molecule drugs. While biologics cannot, by nature, have a technical generic equivalent, there are “biosimilars,” or products deemed “highly similar” or “interchangeable” with a referenced biologic.26  Biologics tend to be priced expensively and face less competition from biosimilars than small molecule brand drugs face from generics. Additionally, although biosimilar competition does lower the price of biologics, it does so to a lesser degree compared with the effect of generic entry on small-molecule drug market.27  As a result, Medicaid spending on biologics (14% of prescription drug spending) is outsized compared to the number of prescriptions that Medicaid fills (less than 1 percent of total Medicaid prescriptions).28 

What are recent policy initiatives in Medicaid pharmacy benefits?

Both state and federal policymakers are undertaking efforts to control prescription drug costs. Much state activity in Medicaid pharmacy benefits is focused on the goal of obtaining greater supplemental rebates from manufacturers. Some states are focusing their efforts on high-cost drugs. State are also pursuing broader drug cost initiatives that have implications for Medicaid. At the federal level, the Trump Administration has proposed or undertaken a number of actions targeted at prescription drug costs, many of which have implications for Medicaid.29  Congress is considering a host of legislative proposals related to prescription drugs, such as action to make technical changes to Medicaid rebate rules. (See examples in Box 1).

As policymakers move ahead with efforts to address Medicaid prescription drug spending, understanding the basic structure of the pharmacy benefit and recent trends can help illuminate potential direct and indirect effects, including those on access to care.

Box 1: Examples of State and Federal Actions onMedicaid Prescription Drug Costs

State EffortsNegotiate greater supplemental rebates from manufacturers:

  • New York uses a spending growth cap, under which the state targets drugs with high or quickly-growing costs for additional supplemental rebates or strict utilization review.
  • Other states, including California, are looking into leveraging purchasing power across state programs to obtain greater rebates.

Streamline the supply chain:

  • Ohio and Kentucky have undertaken efforts to streamline the supply chain by eliminating or renegotiating contracts with PBMs.

Focus on high-cost drugs:

  • Louisiana is pursuing a subscription payment model (often called the “Netflix” model) for HCV drugs30 , where the state pays a fixed cost to a manufacturer in exchange for an unlimited number of prescriptions for DAAs for individuals in Medicaid or state prisons.31 
  • Massachusetts32  and Oklahoma,33  are using or proposing value-based contracts for specific drugs, in which payment and rebates are based on a drug’s effectiveness or patient outcomes.

Broader state initiatives:

  • Some states have targeted the rising cost of generics including proposed laws to prevent price gouging and lawsuits to recoup damages from alleged collusion in price increases.
  • Policies to make pricing information more broadly available34  often apply beyond Medicaid but could provide information to help policymakers identify Medicaid pharmacy spending.

Federal Efforts

Trump Administration actions/proposals:35 

  • The FDA has taken steps and announced plans to increase competition among generics36  and biosimilars.37 ,38 
  • The Administration has called for a new Medicaid demonstration authority limited to five states that would allow state Medicaid agencies to create their own Medicaid formularies.
  • Proposed changes to safe harbor rules to encourage point-of-sale rebates for Medicare beneficiaries would also affect Medicaid pharmacy prices.

Congressional/legislative proposals:

  • Technical changes would make it harder for manufacturers to lower their rebate obligations.39 
  • Other policy proposals include elimination of the drug rebate cap, which would increase the rebates due to the inflationary component, and creation of a grace period following introduction of new drugs during which states are not required to cover that drug.
  • Proposals focused on drug spending in Medicare, including proposals to develop alternative payment structures, such as value-based payments would affect Medicaid’s best price requirement.40 

 

  1. Covered Outpatient Drugs Final Rule, Federal Register, Vol. 81, No. 20, February 1, 2016, https://www.gpo.gov/fdsys/pkg/FR-2016-02-01/pdf/2016-01274.pdf. ↩︎
  2. See “Retail Price Survey,” CMS, accessed February 15, 2018, https://www.medicaid.gov/medicaid/prescription-drugs/retail-price-survey/index.html. ↩︎
  3. Participating manufacturers pay rebates directly to states, and states retain a share of the rebate in proportion to their share of the cost of the drug (based on the federal matching rate). The federal share of the rebate is obtained through a reduction in state claims on federally-matched quarterly Medicaid expenditures. ↩︎
  4. 42 USC § 1396r-8(a)(1). ↩︎
  5. There are some exceptions to this rule. For example, states can opt to exclude certain classes of drugs (e.g., cosmetic or hair growth drugs, fertility drugs, smoking cessation or weight loss drugs). States can also require generic substitution ↩︎
  6. 42 U.S.C. 1396r-8 (c) ↩︎
  7. For brand name drugs, the rebate formula is 1) the greater of either i) 23.1% * (Average Manufacturer Price, AMP) or ii) AMP-Best Price, plus 2) the inflationary component, with the exception of certain clotting factors and drugs approved exclusively for pediatric indications. For generic drugs, the rebate formula is 13%*AMP, plus the inflationary component. ↩︎
  8. Medicaid statute defines Best Price as “the lowest price available from the manufacturer during the rebate period to any wholesaler, retailer, provider, health maintenance organization, nonprofit entity, or government entity within the United States.” There are many important exclusions, including the Department of Veterans Affairs, the 340B program, the Department of Defense, the Public Health Service, the Indian Health Service. The Best Price includes rebates in general, but not Medicaid supplemental rebates or rebates provided through the Medicaid Drug Rebate Program. 42 U.S.C. 1396r-8 (c)(1)(C). ↩︎
  9. 42 U.S.C. 1396r-8 (c). See also “Medicaid Payment for Outpatient Prescription Drugs,” (Washington D.C., MACPAC, March 2017), https://www.macpac.gov/wp-content/uploads/2015/09/Medicaid-Payment-for-Outpatient-Prescription-Drugs.pdf. ↩︎
  10. MACStats: Medicaid and CHIP Data Book, MACPAC, December 2018, “Exhibit 28: Medicaid Gross Spending and Rebates for Drug by Delivery System, FY 2017 (millions)”, https://www.macpac.gov/wp-content/uploads/2018/12/December-2018-MACStats-Data-Book.pdf. ↩︎
  11. Kaiser Family Foundation and Health Management Associates, Sates Focus on Quality and Outcomes Amid Waiver Changes: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2018 and 2019, https://modern.kff.org/medicaid/report/states-focus-on-quality-and-outcomes-amid-waiver-changes-results-from-a-50-state-medicaid-budget-survey-for-state-fiscal-years-2018-and-2019/ ↩︎
  12. States that use PBMs in administering the prescription drug benefit in a fee-for-service setting pay the PBM administrative fees for these services. See Medicaid Pharmacy Trend Report, Second Edition, (Magellan Rx Management, 2017), https://www1.magellanrx.com/media/671872/2017-mrx-medicaid-pharmacy-trend-report.pdf. ↩︎
  13. “Medicaid Drug Rebate Program,” CMS, https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html. ↩︎
  14. “Assuring Medicaid Beneficiaries Access to Hepatitis C (HCV) Drugs,” Medicaid Drug Rebate Program Notice, CMS, November 5, 2015, https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Downloads/RxReleases/State-Releases/state-rel-172.pdf. ↩︎
  15. Under the rebate agreement, states may opt to not cover certain specific drugs that are listed in the statute. ↩︎
  16. Kaiser Family Foundation and Health Management Associates, Sates Focus on Quality and Outcomes Amid Waiver Changes: Results from a 50-State Medicaid Budget Survey for State Fiscal Years 2018 and 2019, https://modern.kff.org/medicaid/report/states-focus-on-quality-and-outcomes-amid-waiver-changes-results-from-a-50-state-medicaid-budget-survey-for-state-fiscal-years-2018-and-2019/ ↩︎
  17. State Maximum Allowable Costs are upper limits states apply to multiple-source drugs included on state maximum allowable cost lists. ↩︎
  18. Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2014 Annual Report, Prescription Drug Fee-For Service Programs, CMS, September 2015, https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/2014-dur-summary-report.pdf; Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2015 Annual Report, Prescription Drug Fee-For-Service Programs, CMS, December 2016, https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/2015-dur-summary-report.pdf; Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2016 Annual Report, Prescription Drug Fee-For-Service Programs, CMS, October 2017, https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/downloads/2016-dur-summary-report.pdf; Medicaid Drug Utilization Review State Comparison/Summary Report FFY 2017 Annual Report, Prescription Drug Fee-For-Service Programs, CMS, October 2018, https://www.medicaid.gov/medicaid/prescription-drugs/downloads/drug-utilization-review/2017-dur-summary-report.pdf. See also “Attachment 4 – Generic Drug Substitution Policies” in state DUR Reports, https://www.medicaid.gov/medicaid/prescription-drugs/drug-utilization-review/annual-reports/index.html. ↩︎
  19. Of the states that required more the restrictive requirements, a majority required preauthorization to enable a pharmacist to provide a brand drug when a generic was available. States included other requirements, such as requiring the submission of a MedWatch Form and requiring a medical reason to override the use of a generic, and some implement more than one restrictive requirement. Ibid. ↩︎
  20. Insulin is a biologic drug that has been regulated as a small molecule drug. In March 2020, it will be regulated as biologic drug, which will allow for manufacturers to produce insulin biosimilars. “FDA ‘Confident’ that Interchangeable Insulin Will Be Available After March 2020,” FDANews Drug Daily Bulletin, December 21, 2018, https://www.fdanews.com/articles/189628-fda-confident-that-interchangeable-insulin-will-be-available-after-march-2020. ↩︎
  21. See U.S. Congress, Senate, Special Committee on Aging, Sudden Price Spikes in Off-Patent Prescription Drugs: The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Healthcare System, December 2016, https://www.aging.senate.gov/imo/media/doc/Drug%20Pricing%20Report.pdf. ↩︎
  22. Katherine Young and Rachel Garfield. Snapshots of Recent State Initiatives in Medicaid Prescription Drug Cost Control. (Washington, DC: Kaiser Family Foundation): February 2018, https://modern.kff.org/medicaid/issue-brief/snapshots-of-recent-state-initiatives-in-medicaid-prescription-drug-cost-control/. ↩︎
  23. U.S. Congress, Senate, Committee on Finance, The Price of Sovaldi and Its Impact on the U.S. Health Care System, 114th Congress, 1st session, 2015, http://www.finance.senate.gov/imo/media/doc/1%20The%20Price%20of%20Sovaldi%20 and%20Its%20Impact%20on%20the%20U.S.%20Health%20Care%20System%20(Full%20Report).pdf. ↩︎
  24. The FDA approved Olysio (Janssen) in November 2013, Sovaldi (Gilead Sciences) in December 2013, Harvoni (Gilead Sciences) in October 2014, Viekira Pak (AbbVie) in December 2014, Technivie (AbbVie) in July 2015, Daklinza (Bristol-Myers Squibb) in July 2015, Zepatier (Merck) in January 2016, Epclusa (Gilead Sciences) in June 2016, and Mavyret (AbbVie) in August 2017. ↩︎
  25. Katherine Young. Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs. Kaiser Family Foundation, February 2019, https://modern.kff.org/medicaid/issue-brief/utilization-and-spending-trends-in-medicaid-outpatient-prescription-drugs/ ↩︎
  26. Ibid. ↩︎
  27. See Andrew Mulcahy, Zachary Predmore, and Soeren Mattke, “The Cost Savings Potential of Biosimilar Drugs in the United States,” (Rand Corporation, 2014), https://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE127/RAND_PE127.pdf. ↩︎
  28. Young, op. cit. ↩︎
  29. Katherine Young, How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid? Kaiser Family Foundation, May 2018, https://modern.kff.org/medicaid/issue-brief/how-does-the-trump-administration-drug-pricing-blueprint-affect-medicaid/ ↩︎
  30. Carolyn Y. Johnson, “Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs,” Washington Post, January 10, 2019, https://www.washingtonpost.com/health/2019/01/10/louisiana-adopts-netflix-model-pay-hepatitis-c-drugs/?utm_term=.b962a75edc5d. ↩︎
  31. Eric Sagnowsky, Louisiana Has Picked its ‘Netflix’ Hepatitis C Partner: Gilead’s New Generics Unit, https://www.fiercepharma.com/pharma/louisiana-picks-gilead-subsidiary-to-partner-netflix-model-for-hep-c-drugs ↩︎
  32. Martha Bebinger, Baker Outlines Steps to Lower Medicaid Drug Prices, https://www.nepr.net/post/baker-outlines-steps-lower-medicaid-drug-prices#stream/0 ↩︎
  33. Jennifer Reck, “Oklahoma Signs the Nation’s First State Medicaid Value-Based Contracts for Rx Drugs,” September 25 2018, NASHP, https://nashp.org/oklahoma-signs-first-medicaid-value-based-contracts-for-rx-drugs/. ↩︎
  34. Pfizer, Inc. v. Texas Health and Human Services Commission, and Charles Smith, Executive Commissioner, Findings and Facts and Conclusions of Law, In the United States District Court for the Western District of Texas Austin Division, Filed September 29, 2017. ↩︎
  35. Katherine Young. How Does the Trump Administration Drug Pricing Blueprint Affect Medicaid? Kaiser Family Foundation, May 2018, https://modern.kff.org/medicaid/issue-brief/how-does-the-trump-administration-drug-pricing-blueprint-affect-medicaid/ ↩︎
  36. Beginning in June 2017, the FDA has maintained a list of off-patent, off-exclusivity drugs lacking generic competition. Also in June 2017, the FDA announced it would expedite ANDA reviews until there were three generics on the market for a given brand. The agency is also intending on issuing guidance in the future addressing other activities that diminish generic competition. “FDA Tackles Drug Competition to Improve Patient Access,” FDA News Release, June 27, 2017, https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm564725.htm and Henry Waxman, Bill Corr, Kristi Martin, Sophia Duong, “What Commissioner Gottlieb’s FDA is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help,” April 2018, https://www.commonwealthfund.org/sites/default/files/documents /___media_files_publications_issue_brief_2018_apr_waxman_gottlieb_plan_fda_ib.pdf. ↩︎
  37. Aware of the importance of biologics when considering drug costs, the FDA released the “Biologics Action Plan” in July 2018, which includes items such as providing guidance to improve biosimilar labeling and to provide clarity for manufacturers to demonstrate interchangeability, as well as providing education to health care professionals to explain concepts such as biosimilars and interchangeability “Biosimilars Action Plan: Balancing Innovation and Competition,” FDA, July 2018. See also “FDA Releases Biosimilar Action Plan,” http://www.centerforbiosimilras.com/news/fda-releases-biosimilar-action-plan. ↩︎
  38. Zachary Brennan, “FDA Sets Record for Number of Generic Drug Approvals Again,” October 11, 2018, https://www.raps.org/news-and-articles/news-articles/2018/10/fda-sets-record-number-of-generic-drug-approvals-a. ↩︎
  39. MACPAC, Improving Operations of the Medicaid Drug Rebate Program, June 2018, https://www.macpac.gov/publication/improving-operations-of-the-medicaid-drug-rebate-program/ ↩︎
  40. “Patient Affordability Value and Efficiency Act,” https://www.cassidy.senate.gov/imo/media/doc/PAVE%20Act.pdf. ↩︎
Poll Finding

Where Does Public Opinion Stand on the U.S. Role in Global Health?

Published: Apr 24, 2019

The Kaiser Family Foundation (KFF) has been tracking public opinion on the U.S. role in global health for the last decade. Now, more than two years into President Trump’s administration, the April 2019 KFF Health Tracking Poll examines whether this period, which has been marked by a changing U.S. stance toward international affairs, has shifted the public’s attitudes on these key issues. Has, for example, the administration’s promotion of an “America first” approach, which has included proposed cuts to U.S. global health programs, affected the public’s support for U.S. engagement to improve the health of those in low and middle income countries? Here we provide an overview of our latest findings, and also look at whether there have been any changes over time.

Americans’ Views on the U.S. Role in World Affairs and Global Health

NEW: About 6 in 10 Americans say the U.S. should play at least a major role in improving health for people in developing countries, though most Republicans do not. Learn more in this @KaiserFamFound #globalhealth polling data note

Consistent with previous KFF polling our latest poll finds broad support (68 percent) for the U.S. playing at least a major role in world affairs (Figure 1), and six in ten (58 percent) believing the U.S. should play a “leading role” or “major role” in improving health for people in developing countries (Figure 2). In the latter case, larger shares of Democrats (70 percent) say they want the U.S. to take at least a major role compared to Republicans (37 percent) or independents (55 percent).

Figure 1: Majority Of The Public See A Major International Role For U.S.
Figure 2: Most See A Major Role For U.S. In Improving Health In Developing Countries, Including Large Shares Of Democrats

About half of the public (49 percent) think the U.S. is spending “too much” on foreign aid, similar to previous KFF poll findings (we have also found that the public greatly overestimates what is spent on foreign aid. See: https://www.kff.org/global-health-policy/poll-finding/americans-views-on-the-u-s-role-in-global-health/). However, when asked about U.S. spending specifically on efforts to improve health in developing countries, a much smaller proportion (29 percent) say the U.S. is spending “too much,” with a majority saying U.S. spending is “about the right amount” (31 percent) or “too little” (29 percent) (Figure 3).

Figure 3: Half Say U.S. Is Spending Too Much On Foreign Aid, But Fewer Say The Same About Improving Health In Developing Countries

Americans’ Views on the Trump Administration and Global Health

In assessing the Trump administration’s efforts, nearly half (46 percent) believe it has made improving health for people in developing countries “a lower priority” compared to previous U.S. presidential administrations with few (5 percent) saying it has made it “a higher priority.” Nearly four in ten (36 percent) would like to see the Trump administration make improving health for people in developing countries “a higher priority” (Figure 4).

Figure 4: Nearly Half Say Global Health Is a Lower Priority in Trump Administration; Nearly Four in Ten Want It To Be A Higher Priority

Americans’ Views on U.S. Participation in joint efforts in global health

In terms of how the U.S. should invest in global health, more than twice as many Americans believe the U.S. should participate in joint “international efforts” to improve global health (67 percent) than say the U.S. should “operate on its own” (26 percent) (Figure 5). This holds across party, though the divide is larger among Democrats (78 percent v. 17 percent) and independents (70 percent v. 25 percent), compared to Republicans (57 percent v. 36 percent).

Figure 5: Majorities Across Parties Believe U.S. Should Participate In Joint International Efforts When Giving Aid To Improve Global Health

In fact, over the last ten years, the public has become even more in favor of U.S. participation in joint international efforts (Figure 6). In 2009, 55 percent of Americans expressed that opinion, compared to 67 percent in our most recent KFF Health Tracking Poll. The share saying the U.S. should operate on its own decreased from 39 percent to 26 percent over that same time period. These views are at odds with the current direction of the administration, which has moved to reduce U.S. engagement in joint international efforts and initiatives.

Figure 6: Public Has Become Even More In Favor Of U.S. Participation In Joint International Efforts To Improve Global Health

Evidence of Increased Partisanship regarding Support for U.S. Global Health Spending

At the same time, there has been an increasing partisan divide regarding views of U.S. spending on global health. In 2009, one-fourth (23 percent) of Republicans and one in seven (14 percent) Democrats said they felt the U.S. was spending “too much” on efforts to improve health for people in developing countries. Ten years later, the share of Republicans who express this view grew 17 percentage points (up to 40 percent) while among Democrats, the share is still about one in seven (17 percent) (Figure 7).

Figure 7: Republicans’ Views Of Global Health Spending Have Become Increasingly Negative, Widening The Partisan Divide On Issue
Poll Finding

KFF Health Tracking Poll – April 2019: Surprise Medical Bills and Public’s View of the Supreme Court and Continuing Protections for People With Pre-Existing Conditions

Authors: Ashley Kirzinger, Bryan Wu, and Mollyann Brodie
Published: Apr 24, 2019

Findings

Key Findings:

  • The Affordable Care Act’s (ACA) protections for people with pre-existing medical conditions continue to weigh heavily on the minds of Americans, especially in light of the ongoing legal battle on the future of the ACA. The majority of the public say they do not want to see the Supreme Court overturn either the pre-existing condition protections (68 percent) or the entire health care law (54 percent); and most – including about half of Republicans – also say it is “very important” to them that the ACA provisions protecting people with pre-existing conditions remain law even after hearing that these protections may have led to increased insurance costs for some healthy people.
  • A majority of Americans also say they are worried that they or someone in their family will lose coverage or will not be able to afford coverage in the future if the Supreme Court eventually hears the case and overturns either the entire health care law or the ACA’s protections for people with pre-existing conditions.
  • Addressing health care costs are on the forefront of the public’s mind when it comes to their priorities for Congress with far more Americans saying targeted actions on prescription drug costs (68 percent), protections for pre-existing conditions (64 percent), and surprise medical bills (50 percent) are the “top priority” for Congress compared to broader reforms like implementing a national Medicare-for-all plan (31 percent), or repealing and replacing the ACA (27 percent).
  • In light of recent legislative activity surrounding surprise medical bills, KFF polling finds broad support across partisans for the federal government taking actions to protect patients from having to pay the cost incurred from an inadvertent out-of-network provider including during a medical emergency and for treatment by an out-of-network doctor or specialist. Partisans do disagree on who should cover the cost of the care if the government takes action. While few (5 percent) say the doctor or provider should solely be responsible for the cost of the care, the public is divided in whether the insurance company, alone, should cover the cost (43 percent) or if the insurance company and the doctor or provider should share in covering the cost (47 percent).
  • This month’s KFF Health Tracking Poll continues to find a majority of the public (56 percent) favor a national Medicare-for-all plan and half holding favorable views of the ACA. About four in ten hold unfavorable views of either a national Medicare-for-all plan (38 percent) or the ACA (38 percent).

Health Care Priorities for Congress

Poll: Most Americans want Congress to prioritize targeted actions that address personal health care costs; fewer cite broader reforms like Medicare-for-All and ACA Repeal

Lowering prescription drug costs and continuing the Affordable Care Act’s (ACA) protections for people with pre-existing conditions top the public’s priorities for Congress. Nearly seven in ten Americans (68 percent), including majorities of Democrats (77 percent), Republicans (66 percent), and independents (64 percent), say lowering prescription drug costs for as many Americans as possible is a “top priority” for Congress. This is followed closely by nearly two-thirds of the public (64 percent), including eight in ten Democrats (82 percent), six in ten independents (62 percent), and half of Republicans (47 percent) who say making sure the ACA’s protections for people with pre-existing health conditions continue is a “top priority” for Congress. Fewer – but still half – say protecting people from surprise medical bills is a “top priority.” This is consistent with the January KFF Health Tracking Poll released earlier this year, which found a similar ranking of the public’s priorities for Congress.

Figure 1: Two-Thirds Say Lowering Drug Costs And Continuing ACA’s Pre-Existing Conditions Protections Should Be Top Priorities

About three in ten say implementing a national Medicare-for-all plan (31 percent), repealing and replacing the ACA (27 percent), or expanding government financial help for those who buy their own coverage on the ACA marketplaces (26 percent) are top priorities for Congress. About half of Republicans say repealing and replacing the ACA is a top priority (52 percent), while a similar share of Democrats (47 percent) say implementing a national Medicare-for-all plan is a top priority.

Table 1: Prescription Drug Costs and Pre-Existing Condition Protections Top Public’s Health Care Priorities for Congress; Democrats and Republicans Also Prioritize Partisan Ideas
Percent who say the following is a top priority for Congress to work on:TotalDemocratsIndependentsRepublicans
Lowering prescription drug costs for as many Americans as possible68%77%64%66%
Making sure the ACA’s pre-existing condition protections continue64826247
Protecting people from surprise high out-of-network medical bills50554945
Implementing a national Medicare-for-all plan31472614
Repealing and replacing the ACA27162252
Expanding government financial help for those who buy their own insurance coverage on the ACA marketplace to include more people26362318

The most recent KFF Health Tracking Poll continues to find that at least three-fourths of Democrats hold favorable views of the 2010 Affordable Care Act (ACA) while a majority of Republicans (77 percent) continue to hold unfavorable views of the ACA. To view partisan attitudes over time, check out our ACA interactive.

Similar to the views of the 2010 Affordable Care Act, the most recent KFF Health Tracking Poll finds the public’s support for a national health plan, or Medicare-for-all, is also basically holding steady since the 2016 presidential election, when Democratic candidate Sen. Sanders made it a hallmark of his campaign, with 56 percent of the public favoring such a proposal. See more at our KFF tracker.

Figure 2: Nearly Six In Ten Of The Public Continue To Favor Medicare-for-all

This month’s tracking poll also examined whether the public’s reaction to a variety of terms used to describe the idea of expanding health insurance coverage to all Americans had changed in light of increased national attention to such proposals. The results are very similar to the November 2017 KFF Health Tracking Poll with “universal health coverage” (63 percent), “Medicare-for-all” (63 percent), and “national health plan” (59 percent) garnering the most positive reactions. Fewer report a positive association to “single payer health insurance system” (49 percent) or “socialized medicine” (46 percent).

Figure 3: Terminology Affects Public Opinion On A National Health Plan

There is some evidence that views of “Medicare-for-all” are becoming increasingly partisan. For example, there has been an uptick in the share of Democrats who say they have a “very positive” reaction to “Medicare-for-all,” up from 49 percent in 2017 to 58 percent in the most recent tracking poll. There has also been a slight uptick among Republicans who have a “very negative” reaction to the term, from 42 percent in 2017 to 51 percent in 2019.

Figure 4: More Than Half Of Democrats And About Half Of Republicans Now Report Strong Partisan Reactions To Medicare-for-all

Partisan Views Of Their Party’s Health Care Agenda

This month’s tracking poll also examines partisans’ view of some congressional actions on health care and finds that both Republicans and Democrats are generally supportive of their party’s platforms.

The Graham-Cassidy proposal, first introduced by the Republican lawmakers during ACA repeal efforts in 2017, replaces funding for the ACA’s Medicaid expansion and individual insurance market subsidies with a block grant program. The proposal caps funding but also allows more state flexibility in how to spend the funding such as deciding who to cover and what protections should be in place for consumers. Overall, six in ten Republicans and Republican-leaning independents support such a proposal while about three in ten (31 percent) oppose.

Figure 5: Most Republicans Support Medicaid And ACA Block-Grant Plan

On the other side of the aisle, this month’s tracking poll finds Democrats and Democratic-leaning independents similarly supporting their party’s leaders on health care. About half say they want Democrats in Congress to focus their efforts on improving and protecting the ACA (52 percent) while a smaller share, but still four in ten (39 percent), say they want Democrats in Congress to focus on passing a national Medicare-for-all plan. This is a slight shift from last month, but could be due to the increased media coverage of the Trump administration’s threats to the ACA during the past few weeks.

Figure 6: About Half Of Democrats And Democratic-Leaners Want Congress To Focus On Improving And Protecting The ACA

Pre-Existing Condition Protections

On December 14, 2018, a federal district court judge in Texas issued a ruling challenging the future of the 2010 Affordable Care Act (ACA).The judge sided with Republican state attorneys general and ruled that, since the 2017 tax bill passed by Congress zeroed out the penalty for not having health insurance, the ACA is invalid. Last month, the Trump administration filed a brief stating that the administration supports the federal judge’s ruling that all of the ACA is invalid. Previously, the Trump administration had stated as part of the lawsuit known as Texas v. United States, it will no longer defend the ACA’s protections for people with pre-existing medical conditions.

The two most high-profile ACA protections for people with pre-existing conditions are that the law prohibits insurance companies from denying coverage based on a person’s medical history (known as guaranteed issue), and the law prohibits insurance companies from charging those with pre-existing conditions more for coverage (known as community rating). The majority of the public say it is “very important” to them that these two ACA provisions protecting those with pre-existing conditions remain law even after hearing that these protections may have led to increased insurance costs for some healthy people. This includes majorities of all partisans saying it is “very important” that these protections remain law as well among those who live in a household without a pre-existing medical condition – the population that may be paying more for coverage.

Overall, seven in ten say it is “very important” to them that the provision that prohibits health insurance companies from denying coverage because of a person’s medical history remains law. An additional one-fifth (19 percent) say it is “somewhat important” this provision remains law. Similarly, about two-thirds (64 percent) say it is “very important” that the provision that prohibits health insurance companies from charging sick people more remains law, while an additional one in five (22 percent) say it is “somewhat important.”

Figure 7: Majorities Say Pre-Existing Condition Protections Are Very Important To Them

This month marks a slight uptick among the share of Republicans who say it is “very important” to them that these provisions remain law even if this means some healthy people may pay more for coverage. The share of Republicans who say it is “very important” to them that guaranteed issue remains law is up seven percentage points, from 47 percent last year to 54 percent. Similarly, the share of Republicans who say it is “very important” that the prohibiting of community rating remains law is up 10 percentage points, from 41 percent to 51 percent.

A larger share of the public say they do not want to see the Supreme Court overturn the ACA’s pre-existing condition protections (68 percent) than say they do not want the Supreme Court to overturn the entire 2010 health care law (54 percent), but still a majority say they do not want this to happen. While a majority of Republicans want the Supreme Court to overturn the ACA, less than half (44 percent) say they want to see the ACA’s protections for people with pre-existing conditions overturned.

Figure 8: Half Of Republicans Do Not Want The Supreme Court To Overturn The ACA’s Pre-Existing Condition Protections

A majority of the public say they are worried (either “very worried” or “somewhat worried”) that they or someone in their family will lose coverage or will not be able to afford coverage in the future if the Supreme Court eventually hears the case and overturns either the entire health care law or the ACA’s protections for people with pre-existing conditions. Nearly half (46 percent) are “very worried” they won’t be able to afford coverage if the ACA is overturned or if the pre-existing condition protections are overturned (44 percent). Slightly fewer – but still about four in ten – are “very worried” they would lose coverage if either the ACA or the protections for people with pre-existing condition protections are overturned by the Supreme Court (39 percent, both).

Table 2: Majorities Are Worried They Would Lose Coverage Or Be Unable To Afford Coverage In The Future If The Supreme Court Overturns ACA Or Protections For People With Pre-existing Conditions
How worried are you that you or someone in your family will…if the Supreme Court overturns the entire health care law?Very worriedSomewhat worriedNot too worriedNot at all worried
…not be able to afford coverage in the future…46171323
…lose coverage in the future…39171430
How worried are you that you or someone in your family will…if the Supreme Court overturns the ACA protections for people with pre-existing conditions?Very worriedSomewhat worriedNot too worriedNot at all worried
…not be able to afford coverage in the future…44181621
…lose coverage in the future…39181626

Individuals in households with a pre-existing condition are more likely than their counterparts to say they are worried about affording coverage or losing coverage if either the entire ACA or the protections for people with pre-existing conditions are overturned. Across all measures, about six in ten of those living in households with a pre-existing condition say they are worried about their coverage compared to about half of those living in households without a pre-existing condition.

While the Texas v. United States lawsuit is still making its way through the U.S. court system, the Trump administration has passed new rules promoting the sale of short-term health insurance policies, which generally have lower premiums compared to ACA-compliant plans but are not required to cover the same benefits or people with pre-existing conditions. While it is still unclear how many people purchased short-term plans during this year’s open-enrollment period, KFF polling finds that the majority of the public wants the federal government to require insurance companies to include a certain set of benefits as well as coverage for pre-existing conditions.

Majorities, across party identification, think the federal government should require health insurance companies to cover a certain set of benefits and cover pre-existing conditions (67 percent) rather than allow them to sell short-term plans that cost significantly less but provide fewer benefits and do not cover some pre-existing conditions (26 percent). Majorities of Democrats (83 percent), independents (62 percent), and Republicans (53 percent) think the federal government should require health insurance plans to cover a certain set of benefits and cover pre-existing conditions.

Figure 9: Majorities Believe The Government Should Require Health Plans To Cover Essential Benefits And Pre-Existing Conditions

Surprise Medical Bills

While many health care issues have policymakers divided, both President Trump and Congress have recently announced plans to tackle “surprise medical bills.” The term, “surprise medical bills,” describes charges from when an insured individual inadvertently receives care from an out-of-network provider.1  Last summer, KFF polling found that two-thirds of Americans said they were either “very worried” or “somewhat worried” about being able to afford their or a family member’s unexpected medical bill. This month’s KFF Health Tracking Poll, perhaps unsurprisingly, finds broad support across partisans for the federal government taking actions to protect patients from having to pay the cost incurred from an inadvertent out-of-network provider. At least three-fourths of the public say the federal government should take action to protect patients from covering the cost of care when the experience the following:

  • they are taken to an emergency room by an out-of-network ambulance (78 percent),
  • they are taken to an out-of-network emergency room during a medical emergency (78 percent), or
  • they are at an in-network hospital but treated by an out-of-network doctor or specialist (76 percent).

Figure 10: At Least Three-Fourths Say The Government Should Take Action To Protect Patients From Surprise Medical Bills

Majorities of Democrats, independents, and Republicans say the federal government should take action to protect patients from paying the cost of care in each of these instances. A larger share of Democrats and independents than Republicans say the federal government should take action to protect patients from each of the examples provided, but still a majority of Republicans say the federal government should take action.

Figure 11: Those Reporting Loneliness Express Dissatisfaction with the Number of Meaningful Personal Connections They Have

If the government takes actions to protect patients from having to pay for the cost of their care, there is not a consensus on whether insurers, or providers, or both, should cover the cost. Few say the doctor or provider should solely be responsible for the cost of the care but the public are divided in whether the insurance company, alone, should cover the cost or if the insurance company and the doctor or provider should share in covering the cost. About half say both the provider and the insurance company should cover the cost of care (47 percent) while a similar share say the insurance company, alone, should cover the cost of care (43 percent).

Figure 12: Public Divided On Who Should Pay If The Government Takes Action To Protect Patients Against Surprise Medical Bills

Four in ten (41 percent) insured adults ages 18-64 say there has been a time in the past two years when they or a family member received care from a doctor, hospital, or lab that they thought was covered and their health plan didn’t cover the bill at all or covered less than they expected. For many of these families (one in five insured adults ages 18-64), this surprise bill was related to care received from an out-of-network provider.2 

Figure 13: Four In Ten Insured Adults, 18-64, Say Their Family Had An Unexpected Medical Bill; One In Five Had A Surprise Medical Bill

Health Care in President Trump’s Budget Proposal

In March 2019, the Trump administration released their latest budget proposal, which included cuts to both Medicare and Medicaid as well as stated support for legislation known as the “Graham-Cassidy proposal.”

This month’s tracking poll finds few Americans wanting to see Congress “decrease spending” on either Medicare (7 percent) or Medicaid (12 percent), with at least four in ten saying they want to see Congress “increase spending” on each of these (47 percent and 42 percent, respectively).

Figure 14: Few Want Congress To Decrease Spending On Medicare And Medicaid

There are strong partisan differences with a majority of Democrats wanting Congress to “increase spending” on Medicare and Medicaid (65 percent and 61 percent, respectively), while most Republicans want to see spending levels “stay about the same” (58 percent and 52 percent, respectively). Independents are divided between wanting Congress to “increase spending” and “keep spending about the same.”

Figure 15: Most Democrats Want Increased Spending On Medicare And Medicaid While Republicans Want To Keep Spending The Same

Methodology

This KFF Health Tracking Poll was designed and analyzed by public opinion researchers at the Kaiser Family Foundation (KFF). The survey was conducted April 11th–16th 2019, among a nationally representative random digit dial telephone sample of 1,203 adults ages 18 and older, living in the United States, including Alaska and Hawaii (note: persons without a telephone could not be included in the random selection process). The sample included 290 respondents reached by calling back respondents that had previously completed an interview on the KFF Tracking poll more than nine months ago. Computer-assisted telephone interviews conducted by landline (301) and cell phone (902, including 624 who had no landline telephone) were carried out in English and Spanish by SSRS of Glen Mills, PA. To efficiently obtain a sample of lower-income and non-White respondents, the sample also included an oversample of prepaid (pay-as-you-go) telephone numbers (25% of the cell phone sample consisted of prepaid numbers) as well as a subsample of respondents who had previously completed Spanish language interviews on the SSRS Omnibus poll (n=10). Both the random digit dial landline and cell phone samples were provided by Marketing Systems Group (MSG). For the landline sample, respondents were selected by asking for the youngest adult male or female currently at home based on a random rotation. If no one of that gender was available, interviewers asked to speak with the youngest adult of the opposite gender. For the cell phone sample, interviews were conducted with the adult who answered the phone. KFF paid for all costs associated with the survey.

The combined landline and cell phone sample was weighted to balance the sample demographics to match estimates for the national population using data from the Census Bureau’s 2017 American Community Survey (ACS) on sex, age, education, race, Hispanic origin, and region along with data from the 2010 Census on population density. The sample was also weighted to match current patterns of telephone use using data from the January-June 2018 National Health Interview Survey. The weight takes into account the fact that respondents with both a landline and cell phone have a higher probability of selection in the combined sample and also adjusts for the household size for the landline sample, and design modifications, namely, the oversampling of prepaid cell phones and likelihood of non-response for the re-contacted sample. All statistical tests of significance account for the effect of weighting.

The margin of sampling error including the design effect for the full sample is plus or minus 3 percentage points. Numbers of respondents and margins of sampling error for key subgroups are shown in the table below. For results based on other subgroups, the margin of sampling error may be higher. Sample sizes and margins of sampling error for other subgroups are available by request. Note that sampling error is only one of many potential sources of error in this or any other public opinion poll. Kaiser Family Foundation public opinion and survey research is a charter member of the Transparency Initiative of the American Association for Public Opinion Research.

GroupN (unweighted)M.O.S.E.
Total1,203±3 percentage points
Party Identification
Democrats342±6 percentage points
Republicans273±7 percentage points
Independents437±6 percentage points
Democratic-leaning independents199±8 percentage points
Republican-leaning independents181±8 percentage points

 

Endnotes

  1. K. Pollitz (2016). Surprise Medical Bills. Kaiser Family Foundation. Available at https://modern.kff.org/private-insurance/issue-brief/surprise-medical-bills/ ↩︎
  2. The August 2018 KFF Health Tracking Poll found that one in ten insured individuals between the ages of 18 and 64 reported having a surprise out-of-network bill. The April 2019 KFF Health Tracking Poll provides a household measure. ↩︎
News Release

Poll: Most Americans Want Congress to Prioritize Targeted Actions that Address Personal Health Care Costs; Fewer Cite Broader Reforms like Medicare-for-All and ACA Repeal as Top Priorities

Bipartisan Support for Government Actions on Surprise Medical Bills, But Views are Divided on Who Should Cover the Cost

Published: Apr 24, 2019

Most Do Not Want the Supreme Court to Overturn the ACA or its Pre-Existing Conditions Protections

When it comes to tackling pressing health care issues, incremental actions to address personal health care costs take precedence over broader, more partisan reforms for most Americans, according to the latest KFF Health Tracking Poll.

As policymakers jockey over Medicare-for-all proposals and the legal and political fate of the Affordable Care Act, the public is more likely to choose lowering prescription drug costs (68%), continuing ACA protections for people with pre-existing conditions (64%) and softening the financial blow of surprise medical bills (50%) as top priorities for Congress. The April poll finds that fewer Americans say implementing a national Medicare-for-all plan (31%) or repealing and replacing the ACA (27%) should be a top priority.

Larger shares of Democrats say continuing the ACA’s protections for people with pre-existing conditions (82%) and implementing a national Medicare-for-all plan (47%) are top priorities, while about half of Republicans (52%) say repealing and replacing the ACA is a top priority.

The April poll continues to find bipartisan support for the ACA’s protections for people with pre-existing conditions. Seven in 10 Americans  say it is “very important” to them that the ACA provision that prohibits health insurance companies from denying coverage because of a person’s medical history remains law. Similarly, two-thirds (64%) say it is “very important” that the provision that bars insurers from charging sick people higher premiums remains law. This includes half of Republicans who say it is “very important” that each provision remains law (54% and 51%, respectively).

The findings come at a time when President Trump has renewed his calls to repeal and replace the ACA and when his administration has sided with the Republican state attorneys general in Texas v. United States, a federal lawsuit that argues that the ACA is invalid and should be overturned. The poll finds that, if the Supreme Court eventually hears the case, most Americans do not want the justices to overturn the pre-existing condition protections (68%) or the entire law (54%). Majorities are worried that they may lose coverage or pay more for coverage.

With both President Trump and Congress vowing to address the issue of surprise medical bills in recent weeks, the poll find that at least 3 in 4 Americans – including majorities of Democrats, independents and Republicans – say the federal government should protect patients from having to cover the higher costs that can arise when they are:

  • Taken to an emergency room by an out-of-network ambulance (78%);
  • Taken to an out-of-network emergency room during a medical emergency (78%); or
  • Treated at an in-network hospital by an out-of-network doctor or specialist (76%)

The poll finds there is no agreement about who should cover the bill, however, with the public split over whether both the health provider and the insurance company should absorb the cost (47%) or whether the insurer should cover it alone (43%). Few (5%) say the doctor should be solely responsible.

KFF polling continues to find that surprise medical bills affect a significant share of insured adults. About one in five of insured adults ages 18-64 say that in the past two years they or a family member have received a surprise medical bill resulting from receiving out-of-network care from a doctor, hospital or lab that they thought was covered.

Medicare-for-all Debate May Be Growing More Partisan

With proposals to expand public coverage drawing attention in Congress and in Democratic campaigns for the 2020 presidential election, views of “Medicare-for-all” may becoming more partisan.  While overall reactions to terms such as “universal health coverage” and “Medicare-for-all” have remained relatively unchanged since 2017, the poll shows an uptick in the share of Democrats who now say they have a “very positive” reaction to the term “Medicare-for-all,” from 49 percent in 2017 to 58 percent. At the same time, half of Republicans (51 percent) now say they have a “very negative” reaction to the term compared to 42 percent in 2017.

Methodology

Designed and analyzed by public opinion researchers at KFF, the poll was conducted April 11-16, 2019 among a nationally representative random digit dial telephone sample of 1,203 adults. Interviews were conducted in English and Spanish by landline (301) and cell phone (902). The margin of sampling error is plus or minus 3 percentage points for the full sample. For results based on subgroups, the margin of sampling error may be higher.

Addressing the Opioid Crisis: Medication-Assisted Treatment at Health Care for the Homeless Programs

Authors: Barbara DiPietro, Julia Zur, and Jennifer Tolbert
Published: Apr 4, 2019

Executive Summary

Health Care for the Homeless (HCH) programs, a subset of community health centers that receive special populations funding to address the specific needs of vulnerable and medically complex patients, play a significant role in addressing the opioid epidemic by providing medication-assisted treatment (MAT). MAT, which combines one of three medications (methadone, buprenorphine, or naltrexone) with behavioral therapies, is the standard of care for opioid use disorder (OUD). This brief presents findings from an analysis of health center data on the provision of buprenorphine-based MAT, as well as interviews with providers and administrators from 12 HCH programs about strategies they adopted to implement MAT programs. Key findings include:

  • Among health centers, HCH programs provide a disproportionately large share of buprenorphine-based MAT, although there was wide variation across states. HCH programs accounted for over one-third of both providers who can prescribe buprenorphine and of all patients receiving buprenorphine in 2017, despite serving only 4% of all health center patients. Additionally, the number of providers able to prescribe buprenorphine and the number of patients receiving the medications both more than doubled at HCH programs from 2016 to 2017.
  • Building support with leadership and clinical staff was a key strategy to implementing MAT at HCH programs. Some approaches to achieving this goal included identifying “champions” within HCH programs to advocate for establishing MAT services, consulting with more experienced HCH programs, and addressing concerns about medication diversion.
  • HCH programs also reported the need to invest in staff training and support. Providing training to primary care providers who lacked expertise in treating opioid use disorder (OUD), fostering coordination between primary care and behavioral health staff, dedicating administrative staff for MAT programs, and recruiting waivered providers can help build MAT programs.
  • Another important strategy respondents discussed was the need to create more flexible systems and programs. For example, adjusting schedules to block out dedicated time for MAT patients and adopting a more flexible approach to the therapy component of MAT services improved access to treatment.
  • Fostering community partnerships and accessing available resources helped build MAT programs. HCH programs were able to establish and grow MAT programs by working with community partners, such as local hospitals and social services organizations, and by maximizing available federal, state, and local grant funding for training and treatment. HCH programs also reported educating local homeless service providers on the importance of MAT to recovery to ensure patients could access shelter or housing while they were in treatment.

Looking ahead, HCH programs will likely continue to make more investments in provider training and capacity, find additional strategies to grow programs to meet patient need, and ensure that MAT services are provided as part of the standard of care for OUD.

Issue Brief

Introduction

As providers of comprehensive health care services in medically underserved areas, community health centers play an important role in addressing the opioid epidemic.1  Health Care for the Homeless (HCH) programs are community health centers that serve people experiencing homelessness, who are often disproportionately impacted by SUD, including OUD. Funded through the Health Resources and Services Administration (HRSA), HCH programs receive special populations funding that allows for more intensive services to meet the specific needs of very vulnerable and medically complex patients.2  Of note, HCH grantees are required to provide or arrange for SUD treatment services, and they typically provide more case management, outreach, and other support services than non-HCH health centers.3  In some cases, HCH programs are part of larger health centers, while in other cases they are stand-alone organizations. In 2017, there were 1,373 health centers that served nearly 1.4 million patients experiencing homelessness; 74% (just over 1 million) of these patients were served by 299 HCH programs.4 

The standard of care for OUD is medication-assisted treatment (MAT), which combines one of three medications (methadone, buprenorphine, or naltrexone) with behavioral therapies, and is associated with better outcomes than behavioral therapies alone.5  In order to prescribe buprenorphine to treat OUD, an eligible provider must obtain a waiver from the Substance Abuse and Mental Health Services Administration (SAMHSA).6  Compared to other health centers, HCH grantees are well-positioned to offer MAT services because of a more intensive care model that has long-emphasized integrated behavioral health and primary care coupled with a low-barrier, harm-reduction approach to patient engagement.

This brief describes the provision of buprenorphine (also known by trade names Suboxone®, Zubsolv®, and Subutex®, among others) at HCH programs relative to other health centers, the growth of these services between 2016 and 2017, and the availability of buprenorphine at HCH programs in states hard-hit by the opioid epidemic. It also highlights successful strategies that HCH programs have used to implement buprenorphine-based MAT programs. Findings are based on an analysis of annual data from the Uniform Data System (UDS) on health center patients and services,7  and on interviews with providers and administrators from 12 HCH programs conducted by the National Health Care for the Homeless Council and the Kaiser Family Foundation. These data and strategies can help inform where MAT might be further expanded, and guide efforts to implement MAT programs at other health center programs and more broadly. In this paper, the term “MAT” refers to buprenorphine-based MAT specifically.

Providing Buprenorphine at HCH Programs

HCH programs provide a greater share of buprenorphine treatment compared to their overall patient numbers. In 2017, HCH programs nationally reported having 1,100 providers with a waiver to prescribe buprenorphine, and delivered buprenorphine to 24,400 patients (Figure 1). While HCH programs account for only 4% of all patients served at health centers nationally, over one-third (37%) of buprenorphine-waivered providers and 38% of all patients receiving buprenorphine were affiliated with HCH programs.

Figure 1: Overall Utilization and Utilization of Buprenorphine Services at HCH and non-HCH Health Centers, 2017

Greater patient need as well as a more intensive treatment model that includes SUD services may help to explain why HCH programs are providing a greater share of buprenorphine-based MAT services. These programs serve a patient population that disproportionately struggles with SUDs, to include OUD. Because of the unique needs of their patients, HCH programs are required to offer SUD treatment services, though not buprenorphine-based MAT specifically, as part of their special populations grant. As a result, many of these clinical settings have developed treatment models that integrate primary care and behavioral health services, provide intensive supports, and emphasize lower-barrier approaches to accessing care. This care model strongly positions these programs to provide buprenorphine services specifically, as well as more comprehensive SUD treatment generally.

As with health centers nationally, both the number of buprenorphine-waivered providers as well as the number of patients getting treatment at HCH programs increased significantly between 2016 and 2017. The number of providers increased 82% across HCH programs, from 606 to 1,100, while the number of patients increased 65%, from 14,749 to 24,400 (Figure 2). These increases demonstrate how HCH programs have used resources to respond to the growing demand for treatment as the opioid epidemic has escalated.

Figure 2: Change in the Availability of Buprenorphine at HCH Programs, 2016-2017

While the national data paint a broad picture, the provision of buprenorphine by HCH programs varied widely across states. Not all states (or all HCH programs within a state) are facing the same challenges from the opioid epidemic, and not all HCH programs are expected to be delivering the same level of OUD services. Consequently, while HCH programs in 19 states served fewer than 100 patients in 2017, HCH programs in other states had many providers who could prescribe buprenorphine, were prescribing buprenorphine to large numbers of patients, and had significant year-over-year increases in both MAT providers and patients receiving buprenorphine (Table 1). Between 2016 and 2017, HCH programs in 24 states saw at least a doubling of the number of staff able to prescribe buprenorphine and in 20 states provided buprenorphine-based MAT to at least twice as many patients. Policy changes that now allow nurse practitioners and physician assistants to prescribe buprenorphine may account for some of the increase, as well as numerous funding opportunities to train additional providers and increase capacity for care. HCH programs in several states saw decreases in the number of waivered providers or patients served; however, this decline may result from staff turnover rather than a decreased commitment to providing MAT, or it may reflect a greater availability of treatment options for patients in their communities.

Importantly, in states hardest hit by the opioid epidemic, particularly in New England, the Mid-Atlantic, and parts of the Midwest,8  many HCH programs have active buprenorphine programs. In 15 of the 23 states with the highest opioid-related overdose death rate, at least half of HCH programs are providing buprenorphine, and in nine states, at least two-thirds of all of the HCH programs are providing MAT (Table 2). However, some states continue to have low buprenorphine-based MAT provision among HCH programs, particularly in Kentucky and Tennessee, even though there may be a significant need for these services in their communities. (The data for this report do not indicate why MAT service levels are low in these areas.) Providing buprenorphine-based MAT remains only a small part of the services most HCH programs deliver, but some HCH programs have made a greater commitment to providing MAT than others. HCH programs in three states (CT, RI, and VT) are providing buprenorphine to more than 15% of their patients, and MAT programs in an additional six states (MA, MD, NC, NH, NM, and WV) are serving 5% or more of their total patients. Because health centers tailor their services based on local need, these data highlight where HCH programs are currently providing extensive buprenorphine-based MAT in alignment with community need and where further expansions may be considered. Conversely, in states where OUD may not be the most significant issue, HCH programs may not be prioritizing the development of active buprenorphine programs.

Table 1: Number of Buprenorphine Providers and Patients Served at HCH Programs, 2016 -2017
StateNumber of HCH Programs, 2017Number of Buprenorphine Providers,2016Number of Buprenorphine Providers,2017Change in Number of Buprenorphine Providers,2016-2017Number of Patients Receiving Buprenorphine, 2016Number of Patients Receiving Buprenorphine, 2017Change in Number of Patients Receiving Buprenorphine,2016-2017
Alabama403306767
Alaska248411192181
Arizona3121011
Arkansas1000000
California45156316160303343731340
Colorado531071010797
Connecticut822381677318601087
Delaware202201616
District of Columbia10171709898
Florida168102100371271
Georgia511030344
Hawaii101102323
Idaho25116347236-111
Illinois892415343694351
Indiana6352120467347
Iowa43746014585
Kansas3231066
Kentucky723158479
Louisiana61329180-11
Maine2410615121106
Maryland210133541493-48
Massachusetts765953018602279419
Michigan14112413306731425
Minnesota21105315097
Mississippi220-2000
Missouri349515134119
Montana412103232
Nebraska1000000
Nevada423113615115
New Hampshire34106243373130
New Jersey79134962733-229
New Mexico619523312781504226
New York214810456157633201744
North Carolina109189105582477
North Dakota1000000
Ohio834373541866325
Oklahoma224211160149
Oregon124566216231076453
Pennsylvania62010-101318317
Puerto Rico51216411613620
Rhode Island2182810443422-21
South Carolina413202828
South Dakota2286214524
Tennessee768278335257
Texas1224203131
Utah337486261175
Vermont11316327337097
Virginia424205050
Washington7295829148367219
West Virginia1412838347390
Wisconsin341-3125-7
Wyoming1012004730
Total2996061,10049114,74924,4009,584
SOURCE: National Health Care for the Homeless Council and Kaiser Family Foundation analysis of the 2016 and 2017 Uniform Data System (UDS).
Table 2: Share of HCH Programs Reporting Buprenorphine Patients and HCH Patients Receiving Buprenorphine as a Share of All HCH Patients in Hard-Hit States
StateOpioid-related Overdose Death Rate*Number of HCH ProgramsShare of all HCH Programs Reporting Buprenorphine PatientsPatients Receiving Buprenorphine as a Share of Total HCH Patients
West Virginia43.41100%6%
New Hampshire35.8367%6%
Ohio32.9863%4%
Maryland30.0250%5%
District of Columbia30.01100%1%
Massachusetts29.7771%9%
Rhode Island26.7250%27%
Maine25.22100%3%
Connecticut24.5838%17%
Kentucky23.6714%1%
Michigan18.51436%2%
Pennsylvania18.5650%1%
Vermont18.41100%22%
Tennessee18.1729%2%
New Mexico17.5683%9%
Delaware16.9250%2%
Utah16.4367%4%
New Jersey16.0743%4%
Missouri15.9367%1%
Wisconsin15.8333%<1
North Carolina15.41040%5%
Illinois15.3850%4%
New York15.12162%4%
Source: National Health Care for the Homeless Council and Kaiser Family Foundation analysis of the 2017 Uniform Data System (UDS) and Kaiser Family Foundation’s State Health Facts

Strategies for Successfully Providing Buprenorphine-based MAT at HCH Programs

HCH programs use a number of wide-ranging strategies to overcome common challenges to providing buprenorphine-based MAT services to their patients. These strategies address the need to build support among leadership and clinical staff, provide training and assistance to clinical and non-clinical staff, modify existing systems and adopt flexible programs to enhance capacity and access, and maximize community partnerships resources. The following discussion highlights themes from interviews with CEOs, program administrators, physicians, and behavioral health staff at 12 HCH programs.

Organizational SUPPORT and buy In

Identifying champions within HCH programs who will advocate for establishing MAT programs is essential to building the necessary support from leadership and clinical staff. Initiating MAT services can be difficult when board members, CEOs or other executive leaders, and/or providers do not feel that SUD is an issue that health centers should be prioritizing. This challenge can be particularly acute when leadership or clinical staff refuses to recognize MAT as an evidence-based practice and a standard of care, preferring instead a more traditional abstinence-focused model. To overcome these attitudes and build support within their organizations, respondents reported identifying “champions” within their agencies who were passionate about addressing OUD and were willing to advocate for the benefits of establishing a MAT program. These champions worked to help leadership recognize MAT as a valuable service consistent with the HCH program’s mission. Recruiting champions who can speak to the concerns from both primary care and behavioral health staff can facilitate coordination across the two disciplines.

“The main barrier to setting up programs is having buy-in from organizational leadership and Board members, even if your providers are on board. Not everyone feels addiction is an issue that FQHCs should be solving—we are so busy providing other services and this is just one more thing we’re supposed to do.” (Physician, Virginia)

“Get someone to be a champion for you, do the education, spend time with others doing MAT, and start an internal mentoring program.” (Physician, New York)

“You have to have a champion. There’s a lot of projects going on and if no one is truly passionate about it, it dies off.” (Physician, New Jersey)

Consulting with more experienced HCH programs to share lessons learned and address concerns can reduce barriers to establishing a MAT program. Several programs were able to engage in peer-to-peer technical assistance efforts, to include visiting clinical sites with established MAT programs to talk directly with providers, patients, and leadership. These visits provided insights into how programs were initiated, how they expanded over time, and how they currently operate. They were also able to share lessons learned and strategize approaches to overcome specific challenges. Respondents who had participated in these visits noted that staff returned from the visits energized and committed to starting a program.

“We had staff members go to another FQHC and walk through the details of their program and everyone came back feeling much more confident.” (Program Director, Maine)

Acknowledging and addressing concerns about medication diversion may be necessary to gaining provider support for a MAT program. A number of clinicians expressed concern about repercussions to their medical license if patients divert the medications they are prescribed. At the same time, providers also acknowledged that many patients have successfully self-medicated with buprenorphine purchased on the street, and that accessing traditional treatment programs is often difficult for very vulnerable people struggling with stability. They conceded the use of diverted medications is a harm reduction approach that reduces overdose risk and facilitates a treatment pathway when patients are ready to make a stronger commitment to a more formal addiction program. The conflict between concern over diversion and interest in harm reduction and overdose prevention creates a dynamic that some providers said they struggle to address. Several providers noted the importance of addressing diversion directly with their patients when they suspect or become aware of it happening. Although potentially difficult and tense, these conversations are necessary to reaffirm patients’ commitment to treatment and to ensure the integrity of the MAT program.

“I know people sell their buprenorphine and to me as a provider, it puts my medical license on the line if we don’t monitor use really tight.” (Physician, Utah)

“Diversion isn’t the biggest problem—overdosing and dying is the biggest problem. People don’t use bup[renorphine] to get high.” (Program Director, Maine)

“I see patients all the time who tried buprenorphine on the street and wanted their own place in a program because it worked well for them.” (Physician, DC)

“It’s actually pretty rare that my patient isn’t taking the medication I prescribe for addiction. When that happens, you have an honest conversation together.” (Physician, Virginia)

Staff Training and Support

Providing training and support to primary care providers who lack expertise in treating OUD can increase their willingness to provide MAT services. Some primary care providers expressed a genuine interest in providing MAT, but acknowledged that they did not have the clinical training, skills, or core competencies to confidently screen and treat patients with OUD. As primary care providers, they also recognized that they were ill-equipped to confidently navigate relapse episodes, and some had difficulty finding harm reduction strategies that would continue engaging vulnerable patients in care. In response, respondents from successful MAT programs reported conducting regular trainings on addiction, harm reduction, motivational interviewing, and other evidence-based approaches to build effective skills for engaging patients in treatment. Some also noted having success in pairing new providers with more experienced ones to allow for mentoring. Another approach for programs was to start small with only a few patients, and expand patient caseloads as provider skills and comfort levels increased.

“Start small—you just want a drink of water, not to be blown away by a fire hose.” (CEO, North Carolina)

“Prescribing buprenorphine has brought the joy back into my work and you don’t get that a lot in primary care because everyone’s burned out. You get to see palpable patient success—they aren’t overdosing, they get a job, they reunite with family and friends—it’s incredibly gratifying.” (Physician, New Jersey)

Engaging staff throughout the organization and fostering coordination between primary care and behavioral health staff helps broaden staff support for the program and can improve quality of care for patients. Respondents reported collaborating with a broad range of team members to develop standards of care and program policies that would meet the needs of a vulnerable patient population. They worked to include community health workers, peer specialists, and outreach workers in training opportunities and used these positions to help locate and re‑engage patients who had become disconnected from care. In addition, some program staff reported holding regular case conferences with team members from primary care and behavioral health to address both client-specific issues and program-wide concerns. In addition to addressing specific cases, these meetings served to build stronger working relationships across the two disciplines. Some respondents also reported their programs allow all staff members, including nurses, case managers, and social workers, to refer patients to their MAT programs in order to maximize access to MAT services and increase staff investment in the success of the program.

“Behavioral health counselors and primary care providers are two disciplines that don’t always work well together. We’ve had weekly meetings with everyone involved, get buy-in on patient cases, and agree on how to best support patients with addiction. Establishing a respectful relationship across disciplines takes time and leadership and a commitment to working together.” (Physician, Virginia)

“Now we will be using community health workers and street outreach teams to lower barriers to our rural program.” (Program administrator, Maine)

“A turning point came when NPs (nurse practitioners) and PAs (physician assistants) could prescribe—they were more open to doing this and our program expanded from there.” (Physician, DC)

Dedicating administrative staff for MAT programs can alleviate burdens on clinicians and allow more time for patient care. In addition to training requirements for provider prescribing, federal law also requires providers to keep patient logs and track other administrative data, which can be time-consuming. In response, some HCH programs identified dedicated staff to coordinate the MAT programs, reserve patient visits in provider schedules, and keep track of MAT documentation requirements. Another challenge voiced by many respondents is the requirement from many Medicaid managed care organizations and other insurers to obtain prior authorization before initiating MAT. Respondents noted this process is staff-intensive and creates delays of several days or more before treatment can be started, reducing the window of opportunity to engage a patient in treatment. Having a staff person dedicated to completing prior authorization requests can facilitate obtaining the authorizations in as timely a manner as possible. Respondents also reported working with insurance plans (or the state) to waive prior authorization requirements for those diagnosed with OUD.

“Most of our insurance plans still require prior authorizations. We have two full-time dedicated staff who only do prior authorizations and it’s incredibly time intensive. Most places don’t have the staff to do this.” (Physician, DC)

Setting expectations for participation in MAT programs by current and new staff and recruiting already-waivered providers can help advance acceptance of MAT. Several respondents mentioned that they had encountered other providers who simply did not prefer to work with patients who had SUD, desiring a more traditional primary care scope of practice. While this was often attributed to long-time providers who believed they would be overwhelmed by unmanageable patients, this viewpoint could inhibit MAT services. In turn, clinical leaders said that they now look to hire new providers who already have their waiver, and they set the expectation that MAT participation is part of the model of care provided.

“Coming in for a primary care visit shouldn’t ignore your addiction issues. Providing patient-centered care means addressing all of it—even the messy stuff.” (Physician, New Mexico)

“We’ve had docs say “I just want to do medical and be a good ole family doc and not get into all that”—I don’t hire those people anymore.” (Physician, New Jersey)

program Flexibility

Modifying internal systems to meet the unique demands of MAT programs can increase provider capacity and facilitate patient adherence with treatment. Clinicians at some HCH programs noted that it was difficult to find room in their busy schedules to accommodate frequent visits often needed by MAT patients to refill or adjust their prescription or to “check-in” on their current status with treatment. Many said that their appointment calendar is booked out weeks in advance, leaving little opportunity to add new patients who likely needed more time and attention than they had available. In response, successful HCH programs adjusted schedules to block out dedicated time for MAT patients and made other changes to eliminate barriers to treatment. For example, some HCH programs reserved same-day, walk-in appointments for MAT patients, scheduled evening services to accommodate those who could not access treatment during the day, and created a central call number where patients could get more information. As mentioned above, other staff roles have been used to help support patients, which allows providers more time to focus on clinical care.

“The demand on capacity is huge—I need more staffing for intake, assessment, prescribing and therapy, and I just don’t have it.” (Physician, Utah)

“Starting in January, all our MAT providers will have a block of same day appointments for easy access and follow-up.” (Physician, DC)

Adopting a more flexible approach to the therapy component of MAT services based on patient needs can improve access to treatment. Patients struggling with homelessness and addiction (as well as other issues) may not be able to navigate more structured programs, complete assessments, wait for insurance approvals, or have the time or transportation to attend frequent therapy sessions or visits for prescription refills. As a result of complex patient needs (to include unstable housing), they say engagement in treatment can vary widely with some individuals starting and stopping treatment suddenly, which can be difficult for program continuity and improving patient health outcomes. Some respondents were concerned that patients needed more therapy support in their recovery than they were able to provide, while others stressed the importance of lowering barriers to care by starting treatment immediately rather than requiring a program orientation, extensive assessments, or rigid adherence to an intensive therapy component. These divergent viewpoints illustrate that providers continue to evaluate how best to deliver care to a high-need population requiring intense services.

“We have a highly structured MAT program that works well for our patients who have resources and are more stable, but we found this didn’t work well for more vulnerable patients. Now, we’re developing a low-barrier, rapid-access program to better serve our higher-needs clients.” (Program administrator, Maine)

“I’ll bet only about ¼ of our MAT patients participate in groups regularly, but our experience is that this isn’t possible or desirable—not everyone needs the same approaches and that’s okay.” (Physician, DC)

“We had many conversations about being patient-first, meeting people where they are, and decreasing barriers to treatment. We stopped doing an orientation, started people on treatment on day one, are doing more patient-centered care, and are now partnering with other organizations.” (Physician, New Mexico)

Community partnerships and RESOURCES

Working with community providers and organizations can facilitate access to and reduce barriers to treatment for patients. These partnerships involved local hospitals and other medical providers, as well as housing and social service organizations. To initiate treatment, some HCH programs developed agreements with local hospitals or emergency departments providing the first dose of buprenorphine when patients presented for treatment and then referring them to an HCH program for ongoing care, while others formed partnerships with other community providers, such as the community mental health center, to maximize treatment resources for patients. Some respondents noted that homeless services providers (shelters, housing programs, etc.) may prohibit clients who take medications for OUD, which forces patients to choose between treatment and shelter. These restrictions, in turn, reduce the effectiveness of treatment and the willingness of some providers to invest in developing MAT programs that they feel may have limited impact. In an effort to reduce this barrier, some HCH programs reported working to create a greater understanding of MAT with local homeless service providers to ensure that patients could access shelter or housing while they were in treatment.

“Our partnership with two community mental health centers has worked well to help initiate buprenorphine treatment in a behavioral health setting and refer patients back to our clinic for primary care and ongoing OUD management.” (Program administrator, Maine)

“There’s a ton of rehab places in the city but they are not very flexible—they don’t even allow any medications that help them [patients] stay sober.” (Physician, Texas)

“When our clients live in an abandoned building, buprenorphine alone is not going to solve all their problems—they are afraid for their safety, they are hungry and cold. We need more housing so the treatment can work better.” (Addiction counselor, Maryland)

Maximizing available funding and training resources can help initiate and expand MAT programs. Numerous grant opportunities have been made available from both the Health Resources and Services Administration (HRSA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) to train providers, increase clinical skills, and expand capacity for treatment. Respondents also pointed to grants and other training opportunities from state/local health departments, professional organizations, Project ECHO [an online, peer-to-peer training model], and other sources. With competing priorities and limited funds, particularly for HCH programs in states that have not expanded Medicaid, taking advantage of these federal and other resources can be critical to starting a program and refining it to match patient needs and provider capacity.

“Project ECHO was helpful in overcoming concerns, fears, and worries. We did a buprenorphine ECHO to present cases, get answers, and hear that we weren’t alone.” (Physician, New Jersey)

“DC gave us a grant to build capacity and do more training. We were then able to hire two more behavioral health staff to coordinate the MAT program, do individual therapy, and run the groups.” (Physician, DC)

“HRSA’s support for addiction treatment has allowed us to train more providers and better integrate MAT services throughout our organization.” (CEO, Maryland)

Looking Ahead

As the opioid epidemic continues to escalate, HCH programs will remain on the front lines of providing buprenorphine-based MAT to very vulnerable, high-need patients disproportionately impacted by this crisis. While some HCH programs have not yet begun programs or scaled them to meet community need, many HCH programs are providing significant levels of buprenorphine-based MAT and are rapidly growing the number of patients they are able to serve. These programs have overcome common challenges by adopting strategies that focus on increasing organizational support, facilitating staff training and collaboration, modifying the MAT program to ensure better access, and maximizing community partnerships and available resources. These strategies can be adopted by HCH programs and other health centers, and by other community providers looking for effective ways to expand access to treatment for the millions of people struggling with OUD.

This brief was prepared by Barbara DiPietro of the National Health Care for the Homeless (HCH) Council and Julia Zur and Jennifer Tolbert with the Kaiser Family Foundation. National HCH Council contractor time for work on this publication is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,625,741 with less than 1% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.

Endnotes

  1. Julia Zur, Jennifer Tolbert, Jessica Sharac, and Anne Markus, “The Role of Community Health Centers in Addressing the Opioid Epidemic,” Kaiser Family Foundation, accessed February 2019, https://modern.kff.org/medicaid/issue-brief/the-role-of-community-health-centers-in-addressing-the-opioid-epidemic/. ↩︎
  2. “Health Centers,” Title 42 U.S. Code, Sec 254b Available: http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title42-section254b&num=0&edition=prelim; Accessed: 2/5/19. ↩︎
  3. Ibid ↩︎
  4. Health Resources and Services Administration, “2017 Health Center Data,” accessed February, 2019, https://bphc.hrsa.gov/uds/datacenter.aspx?q=tall&year=2017&state=. ↩︎
  5. Substance Abuse and Mental Health Services Administration, “Medication Assisted Treatment,” accessed January 29, 2019, https://www.samhsa.gov/medication-assisted-treatment. ↩︎
  6. Substance Abuse and Mental Health Services Administration, “Buprenorphine Waiver Management,” accessed January 29, 2019, https://www.samhsa.gov/programs-campaigns/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver. ↩︎
  7. Health Resources & Services Administration. “Uniform Data System (UDS) Resources,” accessed February 2019, https://bphc.hrsa.gov/datareporting/reporting/index.html. ↩︎
  8. Kaiser Family Foundation “Opioid Overdose Death Rates and All Overdose Death Rates per 100,000 Population (Age-Adjusted), accessed February 2019, https://modern.kff.org/other/state-indicator/opioid-overdose-death-rates/. ↩︎

Key Questions About Medicaid Home and Community-Based Services Waiver Waiting Lists

Authors: MaryBeth Musumeci, Priya Chidambaram, and Molly O'Malley Watts
Published: Apr 4, 2019

Issue Brief

Unlike nearly all other Medicaid-covered services, states use optional waivers1  to provide most home and community-based services (HCBS). Seniors, people with disabilities, and those with chronic conditions rely on Medicaid HCBS to live independently outside of nursing homes and other institutions. HCBS waivers enable states to expand Medicaid financial eligibility and offer benefits targeted to a particular population; these waivers also allow states to choose – and limit – how many people are served. States’ ability to cap HCBS waiver enrollment can result in waiting lists when the number of people seeking services exceeds the number of waiver slots available.

Latest @KaiserFamFound survey of home- and community-based service waiver programs finds more than 700K people were on waiting lists nationally in 2017

This issue brief presents the latest data and answers key questions about HCBS waiver waiting lists from the Kaiser Family Foundation’s 17th annual survey of state Medicaid HCBS programs. Appendix Tables contain state-level data. Related briefs present state-level HCBS enrollment and spending data and highlight themes in state HCBS policies.

Key findings about Medicaid HCBS waiver waiting lists include:

  • Over 707,000 people are on HCBS waiver waiting lists in 40 states as of 2017, an increase of eight percent over 2016. People with intellectual and developmental disabilities (I/DD) comprise about two-thirds of total waiver waiting list enrollment, while over one-quarter are seniors and adults with physical disabilities.
  • The data do not support the conclusion that there is a relationship between a state’s ACA Medicaid expansion status and changes in its HCBS waiver waiting list. From 2013 to 2017, a higher share of non-expansion states (69%, 13 of 19) had an increase in waiver waiting list enrollment, compared to the share of expansion states (41%, 13 of 32).
  • Waiting list data alone are an incomplete measure of state capacity and demand for HCBS and are not directly comparable across states. The populations served and how they are defined vary among states, and everyone on waiting lists may not be eligible for services.

Medicaid fills an important gap as the sole source of coverage for most HCBS. While waiver waiting lists suggest some degree of unmet need for HCBS, this reflects and is more accurately attributed to gaps in the U.S. health care system as a whole, not shortcomings of Medicaid alone.

1.  Who are the people on HCBS waiver waiting lists?

Over 707,000 people are on HCBS waiver waiting lists nationally in 2017,2  an increase of eight percent over 2016 (Figure 1 and Appendix Table 1).3  This increase is consistent with the average annual percent change in waiver waiting list enrollment over the last 15 years, which was nine percent. Total national waiver waiting list enrollment has increased each year since 2010.

Figure 1: Medicaid HCBS waiver waiting list enrollment, 2002-2017.

More than three-quarters of states (40 out of 51) report an HCBS waiver waiting list for at least one target population in 2017 (Appendix Table 1).4  Every state offers at least one HCBS waiver targeted to one or more populations.5  The total number of waivers varies by state, depending on the number of populations targeted and/or the waiver authority used.6  Nationally, there are a total of 287 HCBS waivers, including those under Section 1915 (c) and those under Section 1115, across all 50 states and DC, in 2017.7 

Although some people joined waiver waiting lists between 2016 and 2017, others left a waiting list and began receiving waiver services during this period. For example, 67,000 people moved off waiting lists and began receiving services in 2017, in the 27 states that could report such data.8  Waiver waiting lists are dynamic, with some people joining a list to seek services, while others leave the list and begin receiving services. People may move off a waiting list and begin receiving services when a state increases waiver capacity by funding new slots or when an existing waiver enrollee stops receiving services due to a change in income, functional need, age, state residency, or another reason relevant to waiver eligibility.

People with I/DD comprise about two-thirds (67%, about 473,000 in 36 states)9  of total waiver waiting list enrollment (Figure 2 and Appendix Table 1). Seniors and adults with physical disabilities account for over one-quarter (28%, about 201,000 in 20 states)10  of total waiting list enrollment. The remaining five percent of waiver waiting list enrollment is spread among other populations, including children who are medically fragile or technology dependent (about 29,000 in six states),11  people with traumatic brain or spinal cord injuries (TBI/SCI, about 3,400 in eight states),12 ) people with mental illness (about 1,400 in three states),13  and people with HIV/AIDS (about 80 in 1 state.)14 

Figure 2: Medicaid HCBS waiver waiting list enrollment, by target population, 2017.

The waiting period for waiver services averaged 30 months across all waivers with waiting lists in 2017, with substantial variation by target population (Appendix Table 2).15  The average waiting period by population ranged from four months for waivers targeting people with HIV/AIDS to 66 months for waivers targeting people with I/DD.

Almost all (39 of 40) states with waiting lists prioritize individuals with certain characteristics to receive services when slots become available.16  For example, 23 states offer waivers that give priority to individuals who meet specific crisis or emergency criteria, 22 states prioritize people who are moving from an institution to the community, and 19 states prioritize people who are at risk of entering an institution without waiver services (no data shown). Fewer states prioritize individuals based on assessed level of need (9) or age (6). Twenty-two states use more than one priority group.17 

2.  Is there a relationship between HCBS waiver waiting lists and state choices about the ACA Medicaid expansion?

The data do not support the conclusion that there is a relationship between a state’s ACA Medicaid expansion status and changes in its HCBS waiver waiting list. Over the period just prior to ACA expansion through the first four years of expansion coverage (2013 to 2017), a higher share of non-expansion states (69%, 13 of 19) had an increase in HCBS waiver waiting list enrollment, compared to the share of expansion states (41%, 13 of 32) (Figure 3 and Appendix Table 3).18 

Figure 3: Medicaid HCBS waiver waiting list enrollment, by target population, 2017.

Medicaid HCBS waiver waiting lists pre-date the ACA’s Medicaid expansion, which became effective in most states in 2014. As explained above, waiver waiting lists result from the fact that federal Medicaid law allows states to limit and cap waiver enrollment. This program feature has existed since HCBS waiver authority was created in the early 1980s.19  States have reported waiver waiting lists in each year of our HCBS waiver policy survey, dating back to 2002. The increase in the number of people receiving Medicaid HCBS, and the number of people in need of those services, over the years is attributable to a number of factors, including the aging of the population; medical and technological advances that prolong the lifespan, provide previously unavailable treatments for certain conditions, and offer new options to support independent community living; changing individual and societal preferences for HCBS in lieu of institutional care; and state efforts to meet their community integration obligations under the Americans with Disabilities Act (ADA) and the Olmstead decision.20 

The ACA Medicaid expansion includes – and provides a new coverage pathway for – some people with disabilities and chronic conditions who were previously ineligible. While people who receive Supplemental Security Income (SSI) benefits and those dually eligible for Medicare and Medicaid are excluded from the ACA Medicaid expansion group, many expansion adults nevertheless have disabilities and/or chronic health conditions.21  The ACA Medicaid expansion has enabled some people who were not previously eligible for coverage, and otherwise would be uninsured, to gain coverage.22  Some of these people have conditions that may not rise to the stringent level required to establish SSI eligibility, yet still have an ongoing need for health care services. Others may qualify for Social Security Disability Insurance (SSDI) benefits but, without the Medicaid expansion pathway, could be uninsured during the required 24-month waiting period before Medicare eligibility. Medicaid expansion coverage can include access to needed HCBS, such as home health or personal care state plan services; to the extent that those services meet the needs of expansion adults with disabilities or chronic conditions, these adults may choose not to pursue HCBS waiver coverage – and not join a waiver waiting list – because state plan coverage is available to them.23 

3.  Why is waiver waiting list data not directly comparable among states?

Waiting lists are a function of the populations a state chooses to serve and how the state defines those populations; both of these factors vary among states, making waiting lists an incomplete measure of state capacity and demand for HCBS and not directly comparable among states. While all states have waivers serving people with I/DD, seniors, and adults with physical disabilities, fewer states offer waiver services for other target populations. Consequently, there may be a particular population in need of services, but the state does not keep a waiting list because it does not offer a waiver for that population. In addition, all states do not define the eligibility criteria for their waiver target populations in the same way.24  Furthermore, all individuals on waiting lists ultimately may not be eligible for waiver services. For example, 31 states with waiting lists screen individuals for waiver eligibility before they are placed or while they are on a waiting list, while nine states do not. The nine states that do not screen for waiver eligibility comprise 57% (402,000) of the total waiting list population.25 

All states with waiting lists provide non-waiver Medicaid services (i.e., state plan services) to people who are waiting for waiver services. Medicaid state plan services can include some HCBS, such as home health and personal care. Nearly all (93%) of people on waiver waiting lists currently live in the community.26 

Looking Ahead

As the primary payer for long-term services and supports, and the only source of many HCBS that are vital to seniors and people with disabilities and chronic conditions, Medicaid fills an important gap in the spectrum of health care coverage options available today.27  Medicare covers only a limited amount of skilled post-acute care; private insurance typically does not cover HCBS, especially to the extent needed by people who rely on those services to meet daily needs over time; and out-of-pocket costs can be financially prohibitive. Medicaid also plays an essential role by offering federal financing to help states meet their ADA community integration obligations. Until other sources of long-term care coverage become more widely available and affordable, states, providers, and people who need HCBS will continue to rely on Medicaid to provide these necessary services. While waiver waiting lists suggest a degree of unmet need for HCBS, this reflects and is more accurately attributed to gaps in the U.S. health care system as a whole rather than shortcomings of the Medicaid program alone.

Appendix Tables

Appendix Table 1:   Medicaid HCBS Waiver Waiting List Enrollment, by Target Population and by State, 2017 
State Waiting List Enrollment by Target Population Total Waiting List Enrollment:
I/DDSeniorsSeniors & Adults with Physical DisabilitiesAdults with Physical DisabilitiesMed. Fragile/Tech Dep.ChildrenHIV/AIDS Mental HealthTBI/SCI
Alabamaunknown4,1751904,194
Alaska62900629
Arizona000
Arkansas2,83402,834
California01,6503,352*2,6000817,683*
Colorado3,11500003,115
Connecticut1,52101,556231501,6435,001
Delaware00000000
DC000
Florida21,01749,7980020171,016
Georgia6,96680044NR7,810
Hawaii0000000
Idaho000
Illinois19,35400000019,354
Indiana1,3680361,404
Iowa2,62003,27801,2148928,004
Kansas3,67708070004,484
Kentucky5,878002136,091
Louisiana27,50938,480065,989
Maine1,515001,515
Maryland11,02324,000120035,143
Massachusetts00000
Michigan03,22303,223
Minnesota237000237
Mississippi1,6528,6422,86730413,465
Missouri00000
Montana1,524539932,156
Nebraska3,142003,142
Nevada8091981661,173
New Hampshire10500105
New JerseyNR00
New Mexico4,36413,49817,862
New York0NR0unknownNRunknown
North Carolina11,0003,487014,487
North Dakota800311
Ohio68,6440068,644
Oklahoma7,6590427,701
Oregon11099110
Pennsylvania9,5040009,504
Rhode Island000000000
South Carolina10,4090000010,409
South Dakota35000350
Tennessee7,42807,428
Texas217,78635,17928,4160281,381
Utah2,62813903083942,974
Vermont0000
Virginia12,2660NR12,266
Washington000
West Virginia1,317763122,092
Wisconsin2,9341,26404,198
Wyoming194000194
TOTAL: 472,9971,987187,20011,40928,952811,3573,395707,378
NOTES: I/DD = intellectual and developmental disabilities. TBI = traumatic brain injury. SCI = spinal cord injury. Data include § 1915 (c) and § 1115 HCBS waivers. States may offer more than one § 1915 (c) waiver per target population category. NR indicates state did not respond to question. Blank cell indicates state does not have a waiver serving this population. *CA data include § 1915 (c) waivers only; CA did not report waiver waiting list enrollment for its § 1115 waiver for seniors and adults with physical disabilities.SOURCE: KFF Medicaid HCBS Waiver Program Survey, FY 2017.
Appendix Table 2: Average Wait Time by Population for Medicaid HCBS Waivers with Waiting Lists, 2017*
Target Population:I/DDSeniorsSeniors & Adults with Physical DisabilitiesAdults with Physical DisabilitiesMed. Fragile/Tech Dep.ChildrenHIV/AIDS Mental HealthTBI/SCIAll Populations
Average Number of Months Waiting: 66642513334112730
NOTES: I/DD = intellectual and developmental disabilities. TBI = traumatic brain injury. SCI = spinal cord injury. Data include § 1915 (c) and § 1115 waivers. *Of the 40 states reporting one or more waivers with a waiting list in 2017, 27 states reported average wait time for at least one waiver with a waiting list (AL, AK, AR, CA, CO, CT, FL, GA, IN, IA, KS, LA, MD, MI, MS, MT, NE, NV, NH, NM, NC, OK, OR, SD, TX, WV, and WY), and 13 states (IL, KY, ME, MN, ND, NY, OH, PA, SC, TN, UT, VA, and WI) did not report average wait time for any waivers with waiting lists.SOURCE: KFF Medicaid HCBS Waiver Program Survey, FY 2017.
Appendix Table 3: Medicaid HCBS Waiver Waiting Lists by State and ACA Expansion Status, 2013-2017
StateTotal HCBS Waiver Waiting List Enrollment**Change in HCBS Waiver Waiting List Enrollment, 2013-2017^
20132014201520162017IncreaseDecreaseNo Change
Expansion States (32 states)
Alaska*982982935535629X
Arkansas2,8233,0072,8933,2782,834X
Arizona**NRNR000X
California**5,3523,6603,5924,0887,683X
Colorado3,7893,7964,2183,1943,115X
Connecticut1,4862,0782,5092,9035,001X
DCNR0000X
Delaware**NR0000X
Hawaii**NR0000X
Illinois33,11429,42531,47319,16319,354X
Indiana*8,8885,2951,9141,6271,404X
Iowa7,2198,7758,5058,9288,004X
Kentucky4536,2786,2968,1906,091X
Louisiana*57,15641,49262,82873,92965,989X
Maryland26,67327,12945,84436,15635,143X
MassachusettsNR0000X
Michigan*14,04014,04003,3113,223X
Minnesota4,8204,8204,914128237X
Montana*2,7471,2981,5831,3092,156X
Nevada1,1851,2711,3151,3721,173X
New Hampshire*^NR00260105X
New Jersey**50505900X
New Mexico**11,23919,2695,40120,07017,862X
New York**NR0000X
North Dakota^NR00311X
Ohio37,38559,70862,11862,54668,644X
Oregon^NR00134110X
Pennsylvania*18,41018,41618,2959,7289,504X
Rhode Island**NRNR000X
Vermont**NRNR000X
Washington1,3511,350000X
West Virginia4092,1882,2121,5402,092X
TOTAL EXPANSION STATES: 13118
Non-Expansion States (19 states)
Alabama2,6102,6102,7835,2844,194X
Florida51,37976,75083,36567,47971,016X
Georgia11,24211,24212,20110,2707,810X
Idaho*NR0000X
Kansas5,4415,4414,8973,8904,484X
Maine*1,0822,35601,0001,515X
Missouri844684000X
Mississippi8,3387,8437,0359,48113,465X
North Carolina16,56522,05620,73612,06814,487X
Nebraska*1,4011,2991,3682,0623,142X
Oklahoma6,9946,9337,2257,5697,701X
South Carolina6,0045,6562,35511,27510,409X
South Dakota2323340350X
Tennessee**7,1657,1657,5645,8137,428X
Texas**163,146163,146204,550232,068281,381X
Utah*2,1722,1722,2412,5432,974X
Virginia*7,7797,77916,58316,58312,266X
Wisconsin3,9633,9634,3334,2164,198X
Wyoming745621385202194X
TOTAL NON-EXPANSION STATES: 1351
NOTES: NR indicates state did not report data. *State expansion status is as of 2017. All states expanded 1/2014, except AK (9/2015), IN (2/2015), LA (7/2016), ME (1/2019), MI (4/2014), MT (1/2016), NH (8/2014), PA (1/2015), and VA (1/2019). ID, NE, and UT have adopted but not yet implemented expansion. **Data include § 1915 (c) and § 1115 HCBS waivers beginning in 2016, except that CA and NY did not report § 1115 waiver waiting list enrollment; prior years include § 1915 (c) waivers only. ^Change includes 2014-2017 for NH, ND, and OR, as 2013 data are unavailable.SOURCE: KFF Medicaid HCBS Program Surveys, 2013-2017.

Endnotes

  1. Medicaid HCBS waiver authorities include Section 1915 (c) and Section 1115. For additional background on these authorities, see Kaiser Family Foundation, Streamlining Medicaid Home and Community-Based Services: Key Policy Questions (March 2016), https://modern.kff.org/medicaid/issue-brief/streamlining-medicaid-home-and-community-based-services-key-policy-questions/. ↩︎
  2. This total reflects individuals on waiting lists in 39 of 40 states reporting waiting lists for Section 1915 (c) and/or Section 1115 HCBS waivers. It omits New York, which reports a waiting list for people with mental health disabilities but was unable to report the number of individuals on that list. It includes partial data for Alabama, which reported waiting list enrollment for seniors and adults with physical disabilities but reported enrollment on its waiting list for people with I/DD as unknown. It also includes partial data for California, which reported waiting list enrollment for its Section 1915 (c) waivers serving seniors and/or adults with physical disabilities and people with HIV/AIDS, but did not report enrollment on its Section 1115 waiting list for seniors and adults with physical disabilities. In addition, the following states did not respond to the question about whether there is a waiting list for the following target populations: Georgia for people with mental health disabilities, New Jersey for people with I/DD, New York for seniors and adults with physical disabilities and people with TBI/SCI, and Virginia for adults with physical disabilities. ↩︎
  3. Beginning in 2016, totals include Section 1915 (c) and Section 1115 HCBS waiver waiting lists; prior years include only Section 1915 (c) waiver waiting lists. Forty-eight states offer at least one Section 1915 (c) HCBS waiver; the remaining three (AZ, RI, and VT) serve all HCBS populations through Section 1115 waivers. Eight states (CA, DE, HI, NJ, NM, NY, TN, and TX) serve some HCBS populations through Section 1915 (c) waivers and others through Section 1115 waivers. For a timeline of when states began moving populations from Section 1915 (c) to Section 1115 waivers, see Kaiser Family Foundation, Medicaid Home and Community-Based Services Enrollment and Spending (April 2019), https://modern.kff.org/medicaid/issue-brief/medicaid-home-and-community-based-services-enrollment-and-spending. ↩︎
  4. See supra., n.2. ↩︎
  5. See supra., n.3. ↩︎
  6. Each Section 1915 (c) waiver generally is targeted to a particular population, while a single Section 1115 waiver can include multiple populations, each of whom otherwise would have to be served under separate Section 1915 (c) waivers. ↩︎
  7. Kaiser Family Foundation, Medicaid Home and Community-Based Services Enrollment and Spending (April 2019), https://modern.kff.org/medicaid/issue-brief/medicaid-home-and-community-based-services-enrollment-and-spending. ↩︎
  8. Total includes data reported by 27 of 40 states with waiver waiting lists. The other 13 states with waiver waiting lists were unable to report this data (AR, IL, KY, ME, MN, NV, NY, OH, OR, PA, TN, VA, and WI). ↩︎
  9. Thirty-seven of 51 states with waivers serving people with I/DD report waiting lists. Waiting list enrollment includes 36 states. The other state, Alabama, reports unknown enrollment on its waiting list for people with I/DD. In addition, New Jersey did not report whether it has a waiting list for people with I/DD. ↩︎
  10. Twenty of 51 states with waivers serving seniors and/or adults with physical disabilities report waiting lists. Waiting list enrollment reflects partial data for California, which reported waiting list enrollment for its Section 1915 (c) waivers serving seniors and/or adults with physical disabilities but was unable to report waiting list enrollment for its Section 1115 waiver serving these populations. In addition, New York did not report whether it has a waiting list for its Section 1115 waiver serving seniors and adults with physical disabilities. Virginia reported no waiting list for its waiver that serves both seniors and adults with physical disabilities but did not report whether it has a waiting list for another waiver for adults with physical disabilities. ↩︎
  11. Six of 18 states with waivers serving children who are medically fragile or technology dependent report a waiting list. ↩︎
  12. Eight of 25 states with waivers serving people with TBI/SCI report a waiting list. In addition, New York was unable to report whether its TBI/SCI waiver has a waiting list. ↩︎
  13. Four of 14 states with waivers serving people with mental health disabilities report a waiting list. Waiting list enrollment includes three states. The other state, New York, reports unknown enrollment on its waiting list for people with mental health disabilities. In addition, Georgia was unable to report whether its mental health waiver has a waiting list. ↩︎
  14. One of 10 states with waivers serving people with HIV/AIDS reports a waiting list. ↩︎
  15. Of the 40 states reporting one or more waivers with a waiting list in 2017, 27 reported average wait time for at least one waiver with a waiting list (AL, AK, AR, CA, CO, CT, FL, GA, IN, IA, KS, LA, MD, MI, MS, MT, NE, NV, NH, NM, NC, OK, OR, SD, TX, WV, and WY), and 13 (IL, KY, ME, MN, ND, NY, OH, PA, SC, TN, UT, VA, and WI) did not report average wait time for any waivers with waiting lists. ↩︎
  16. The exception is West Virginia. ↩︎
  17. Within a state, some waivers prioritize only one group, while other waivers may give priority to more than one group. ↩︎
  18. States implemented the ACA Medicaid expansion in January 2014, except for AK (9/2015), IN (2/2015), LA (7/2016), ME (1/2019), MI (4/2014), MT (1/2016), NH (8/2014), PA (1/2015), and VA (1/2019). ME and VA are counted as non-expansion states for the time period analyzed in this brief (2013-2017), as are ID, NE, and UT, which have adopted but not yet implemented expansion as of 2019. See generally Kaiser Family Foundation, Status of State Action on the Medicaid Expansion Decision (Feb. 13, 2019). ↩︎
  19. For additional background, see Kaiser Family Foundation, Streamlining Medicaid Home and Community-Based Services: Key Policy Questions (March 2016), https://modern.kff.org/medicaid/issue-brief/streamlining-medicaid-home-and-community-based-services-key-policy-questions/. ↩︎
  20. In Olmstead, the Supreme Court held that the unjustified institutionalization of people with disabilities violates the Americans with Disabilities Act. Kaiser Family Foundation, Olmstead’s Role in Community Integration for People with Disabilities Under Medicaid: 15 Years After the Supreme Court’s Olmstead Decision (June 2014), https://modern.kff.org/medicaid/issue-brief/olmsteads-role-in-community-integration-for-people-with-disabilities-under-medicaid-15-years-after-the-supreme-courts-olmstead-decision/; Kaiser Family Foundation, Medicaid Beneficiaries Who Need Home and Community-Based Services: Supporting Independent Living and Community Integration (March 2014), https://modern.kff.org/medicaid/report/medicaid-beneficiaries-who-need-home-and-community-based-services-supporting-independent-living-and-community-integration/. ↩︎
  21. Previous analysis shows that nearly six in 10 (57%) nonelderly Medicaid adults have a disability but do not receive SSI benefits, meaning that they are eligible for Medicaid through another pathway, such as the Medicaid expansion in states that have adopted that pathway. Kaiser Family Foundation, How Might Medicaid Adults with Disabilities Be Affected by Work Requirements in Section 1115 Waiver Programs? (January 2018), https://modern.kff.org/medicaid/issue-brief/how-might-medicaid-adults-with-disabilities-be-affected-by-work-requirements-in-section-1115-waiver-programs/. ↩︎
  22. Kaiser Family Foundation, The Affordable Care Act’s Impact on Medicaid Eligibility, Enrollment, and Benefits for People with Disabilities (April 2014), https://modern.kff.org/health-reform/issue-brief/the-affordable-care-acts-impact-on-medicaid-eligibility-enrollment-and-benefits-for-people-with-disabilities/. ↩︎
  23. Most ACA expansion states opt to align their expansion adult benefit package with their traditional state plan benefit package, by offering all state plan services to expansion adults if medically necessary. ↩︎
  24. Kaiser Family Foundation, Key State Policy Choices About Medicaid Home and Community-Based Services (April 2019), https://modern.kff.org/medicaid/issue-brief/key-state-policy-choices-about-medicaid-home-and-community-based-services. ↩︎
  25. These states include AK, IA, IL, KY, NE, OH, OK, TN, and TX. ↩︎
  26. Includes data reported by 28 of 40 states with waiver waiting lists. The 12 other states with waiver waiting lists were unable to report this data (GA, IL, KY, ME, MN, NM, OH, PA, TN, TX, VA and WY). ↩︎
  27. Medicaid finances 52% of long-term services and supports nationally in 2017. KFF estimates based on 2017 National Health Expenditure Accounts data from CMS, Office of the Actuary. ↩︎